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A SCREEN FOR PEPTIDES TARGETING CHEMORESISTANT METASTATIC
TRIPLE-NEGATIVE BREAST CANCER
Shraddha Subramanian, B.E
Advisory Professor: Mikhail G. Kolonin, Ph.D.
Cancer metastasis is the principal cause of most cancer-associated morbidities. While
radiotherapy, hormone therapy, and novel therapeutic strategies, including immunotherapy, have
shown promise in inhibiting tumor growth, chemotherapy remains the mainstay in the clinical
management of metastatic progression. This is often the case in triple-negative breast cancer
(TNBC), an aggressive breast cancer subtype where tumorigenesis is independent of HER-2,
progesterone, or estrogen receptor expression. Despite improving TNBC prognosis, recent studies
report that after chemotherapy administration, TNBC drug-tolerant tumor cell survival, relapse,
and metastatic dissemination may be promoted. Overcoming drug resistance exhibited by
metastatic tumor cells is a challenge owing to the lack of specific biomarkers and the absence of
drugs available to selectively target them. The development of such therapeutics would be pivotal
for cancer medicine, as they would enable targeted ablation of the mortality-responsible tumor
cell population with minimal off-side effects.
Our studies indicate that in TNBC mouse models, the chemotherapeutic agent cisplatin
exacerbates spontaneous metastases to the lung. In this project, we have aimed to develop novel
compounds that specifically target chemoresistant cancer metastases. It is based on the hypothesis
that metastatic cancer cells express unique cell surface receptors that can be targeted. To test this
hypothesis, we performed a combinatorial phage-displayed peptide library screen to isolate
phage-displayed cyclic peptides that mimic the natural ligands of novel receptors expressed by
chemoresistant metastatic TNBC tumor cells. These peptides were termed Breast Lung Metastasis
Peptides (BLMPs), owing to their pulmonary metastases-specific tropism. Two lead BLMPs were
v

validated in murine cancer models in vivo and in vitro. We demonstrate that BLMP homing to
pulmonary metastases was independent of chemotherapy administration. Our findings suggest
that the BLMPs localized predominantly along the invasive edges of the pulmonary metastases.
Immunofluorescence assays suggest that the two lead BLMPs are selective for tumor cells
exhibiting a mesenchymal phenotype. BLAST sequence analysis of the two lead BLMP peptides
reveals that they bear homology with biological ligands of receptors implicated in EMT activation
and metastatic progression. To explore the therapeutic potential of these metastatic tumor cellspecific peptides, the BLMPs were modified to generate hunter-killer peptides (HK-BLMPs) that
induce apoptosis upon internalization into targeted cancer cells. We demonstrated that one of the
HK-BLMP peptides selectively kills cancer cells and shows potential in decreasing metastatic
burden in a murine model of spontaneous TNBC metastasis.
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Chapter 1: Introduction

1

1. Breast Cancer
1.1 Epidemiology
The occurrence of breast cancer is heavily skewed by gender. Roughly 1 in 8 women
have a lifetime risk of developing breast cancer, which is orders of magnitude higher than the
corresponding risk in men - around 1 in 1000 (1). Nearly 25% of cancer diagnoses in women
worldwide fall under the category of breast cancer (2), placing this disease second on the list of
common causes of cancer death in women (3). Among women in the US, around 41,760 deaths
were expected in 2019 from a projected 316,700 cases (4). Old age is the next major risk factor
associated with breast cancer followed by factors like race, ethnicity, obesity, alcohol
consumption, physical inactivity, early onset of menstruation, and late/no pregnancy. Advances
in screening techniques, effective treatment, and early detection have contributed to a significant
decrease in the death rate due to breast cancer (by about 40%) over the past 30 years (4). Although
these advancements merit praise, there has been no respite in the incidence of breast cancer, which
continues to be on the rise. This necessitates a more comprehensive strategy to counter the disease
while providing treatment that is both efficient and reliable.

1.2 Breast Cancer Subtyping
Building a systematic strategy for treating breast cancer requires an appropriate
classification of its heterogeneity. Initial attempts used the presence or absence of estrogen
receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2
(HER-2) to develop subtypes (5). Techniques like gene expression profiling are still gaining
traction and require better standardization and cost-effectiveness before they can be used as a
rubric for classification (6). From a clinical perspective, breast cancer continues to be subtyped
on a molecular basis governed by the presence or absence of the receptors mentioned above. The
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four resulting categories are Luminal A, Luminal B, HER-2, and TNBC. Their general relation
with the three receptors is shown in Table 1.

ER

PR

Her-2

Luminal A

+

+

-

Luminal B

+

+

+/-

Her-2

-

-

+

TNBC

-

-

-

Table 1: Breast cancer subtyping: Classification based on hormone receptor expression

1.2.1 Luminal A
The presence of both estrogen and progesterone receptors, along with the absence of
HER-2, characterizes the Luminal A subtype. This is the most commonly occurring subtype, and
it exhibits a slow proliferation rate, which can be inferred through low Ki67 staining. Patients
with Luminal A breast cancer generally receive the most favorable prognosis (7). Treatment for
this subtype is typically contingent on the menopausal status of the patient and their estrogen
source (8). The effectiveness of hormone therapy against Luminal A reduces the recurrence rate
and increases the chance for survival (9, 10). Mutations in PIK3CA, MAP3K1, GATA3, and TP53
genes are common in Luminal A.

1.2.2 Luminal B
This subtype's characteristics differ from Luminal A in one key feature - higher
proliferation rates observable through greater Ki67 staining. Like Luminal A, they express
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estrogen and progesterone receptors, but they may be HER-2 positive or negative. Diagnosis of
this subtype often occurs at a young age, and the large tumor size associated with Luminal B
typically results in poor prognosis. The survival rate for Luminal B patients is second only to
Luminal A (10). The genes PIK3CA, GATA3, and TP53 are commonly mutated in Luminal B.

1.2.3 HER-2
As suggested by the name, this subtype has high expression levels of HER-2 and
typically lacks both ER and PR expression. Patients with HER-2 breast cancer are diagnosed at
an even younger age compared to the two Luminal subtypes. Targeted therapies against HER-2
have gathered pace in recent years (10, 11). These advances are improving the bleak prognosis
that usually accompanies HER-2 breast cancer. The commonly mutated genes in this subtype are
TP53, PIK3CA, and MUC16. These are accompanied by a higher expression of tyrosine kinases
like fibroblast growth factor receptor (FGFR) and epidermal growth factor receptor (EGFR).

1.2.4 TNBC
TNBCs represent a subtype of breast cancers that lack the expression of ER, PR, or
HER-2 genes. It is commonly observed in young patients and accounts for over 15% of newly
diagnosed breast cancer cases (12). At the time of diagnosis, most TNBCs are found to have
progressed to an advanced stage due to the higher grade, larger size, and lymph node involvement
presented by TNBC tumors (13). An additional level of complexity observed to accompany
TNBCs is intra-tumoral and inter-patient heterogeneity (14). Although all TNBC tumors present
a similar gene expression profile, their mutation burden is often non-uniform. No two TNBC
tumors have the same mutations, which accounts for the high inter-patient heterogeneity
encountered clinically. Moreover, the genetic composition of TNBC tumors and thus, their
prognosis varies from patient to patient. TNBCs harbor mutations in vital tumor suppressors such
4

as p53 and BRCA (15). Several critical signaling pathways, including the phosphatidylinositol 3kinase and protein kinase B (PI3K-AKT) pathway, mitogen-activated protein kinase (MAPK),
nuclear factor kappa light chain enhancer of activated B cells (NF- B) pathway, and wingless and
int-1 (Wnt) pathway, are often dysregulated in this cancer subtype (16). To gain more insight into
the intra-tumoral diversity exhibited by TNBCs, a classification based on gene expression profiles
was performed in 386 TNBC tumors (13). This clustering revealed six new TNBC subtypes
namely basal, mesenchymal, mesenchymal stem-like (MSL), immunomodulatory (IM), luminal
androgen receptor (LAR), basal-like 1 (BL1), and basal-like 2 (BL2), each characterized by a
unique gene and pathway signature (13). For instance, the LAR subtype showed enrichment in
metabolic pathways and androgen receptor signaling, while the BL1 subtype exhibited enrichment
in DNA replication and cell cycle pathways (13). Another seminal study that analyzed the RNA
and DNA profiles of 198 TNBC tumors classified them into four distinct molecular subtypes: a)
Luminal androgen receptor (LAR) subtype with up-regulated cell surface mucin expression, b)
Mesenchymal (MES) subtype overexpressing platelet-derived growth factor receptor (PDGFR)
and c-kit growth factor receptors, c) Basal-like immune-suppressed (BLIS) subtype expressing
the immune-suppressing molecule V-set domain-containing T-cell activation inhibitor (VVTCN1) and lastly, d) Basal-like immune activated (BLIS) subtype which expresses signal
transducer and activator of transcription-3 (STAT-3) molecules and cytokines (17).

2. Metastatic Breast Cancer
Metastasis is a convoluted biological phenomenon. It involves cancer cell dissociation
from the primary tumor, invasion of surrounding connective tissue, intravasation into host
vasculature, and entry into circulation. Upon survival in circulation, the tumor cells disseminate
to secondary sites harboring a permissible tumor microenvironment (TME). Here, they
extravasate and form micro-metastases, establish a favorable metastatic niche, and eventually
5

proliferate into macro-metastases (18). The ability to complete each stage of the metastatic
cascade dictates the metastatic potential of the tumor cells.
Although localized primary tumors are the source of malignancy burden, it is the
metastases that attribute to over 90% of all cancer-associated morbidity and mortality (19). Owing
to the genetic instability of metastatic tumors, their treatment is a daunting challenge. In addition
to a unique immunophenotypic profile, TNBCs possess several aggressive clinicopathological
features such as young age of onset and large tumor size (20). These factors promote the
development of distant metastases in several organs, including the lung, brain, and liver.
A large cohort study of over 1600 women with invasive breast cancer reported that the
TNBC patient subgroup reflected tumors that were more aggressive and grew rapidly (21). These
observations were further corroborated by Liedtke and colleagues, who revealed that TNBC
patients had higher recurrence rates when compared to their hormone-sensitive counterparts (22).
Further, these tumors often resemble basal-like breast cancers, which are identified as
poor prognosis subgroups with respect to relapse-free survival and overall survival (OS) (23). The
gene expression profile of most basal-like tumors consists of a myriad of candidate genes that
might contribute to their aggressive phenotype. Since TNBCs and basal-like cancers are believed
to reflect a higher level of genetic instability, it might explain their propensity towards metastatic
progression. Thus, to improve metastatic TNBC (mTNBC) patient outcomes, it is crucial to gain
insight into the cellular and molecular mechanisms that govern metastatic dissemination (24).

3. Epithelial to Mesenchymal Transition and Breast Cancer Metastasis
Epithelial to mesenchymal transition (EMT) is a latent developmental program
implicated in wound healing and tissue regeneration (25). EMT is accompanied by a loss of
apicobasal cell polarity, disruption of adherens junctions, and cytoskeletal reorganization by
which cells acquire a mesenchymal and migratory phenotype (26). In cancer, a hijacked EMT
6

program endows metastasis favoring characteristics upon the cancer cells (27). An
armamentarium of cell surface markers, cytoskeletal organization proteins, transcription factors,
microRNAs, ligands, and growth factors work in unison to choreograph this intricate process (28).
The reverse process, termed mesenchymal to epithelial transition (MET), is also highly regulated
during development (28, 29). Distant metastases resemble the molecular subtype of their primary
tumor, and several studies have proved that the disseminated cancer cells are often epithelial (30,
31). The term plasticit

describes the abilit of cells to transition seamlessl between the

epithelial and mesenchymal phenotypes. While the migratory and invasive features of cancer cells
initiate the metastatic cascade, its completion is contingent upon the plasticity between
EMT/MET (32).
EMT is primarily induced through alterations in gene expression, that enables cells to
acquire mesenchymal properties. During EMT, cells demonstrate epithelial cadherin (E-cadherin)
repression and neural cadherin (N-cadherin) up-regulation simultaneously (33). The cadherin
switch, a prominent EMT hallmark, is observed regardless of cell type or EMT-inducing factor
(34). The Snail family of transcription factors induces the mesenchymal phenotype through the
epigenetic inhibition of E-cadherin. Snail is also responsible for turning on the expression of
mesenchymal markers such as N-cadherin, collagen, fibronectin, matrix metalloproteases
(MMPs), Twist, and zinc finger e-box binding homeobox-1 (ZEB-1) (34). EMT can also be
triggered by hypoxia and other extracellular stimuli, including tumor necrosis factor-alpha (TNF), transforming growth factor-beta (TGF- ), EGF, FGF, and PDGF, to name a few. Signal
transduction pathways, including Wnt, Notch, NF- B, MAPK, and PI3K pathways, are also
reported to coordinate the EMT program (35). The transcriptional factors and the hallmarks of
EMT are often associated with a malignant phenotype in breast cancer patients. The high
expression of Slug and Twist was demonstrated to closely correlate with poor prognosis in breast
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cancer patients (36, 37). Further, Jeong and colleagues underscored that EMT was related to a
high histological grade and the triple-negative phenotype (38).

4. Treatment Modalities of Triple-Negative Breast Cancer
Patients with TNBC fail to respond to hormone-based therapy due to the absence of
ER, PR, and HER-2 target receptor expression. Thus, surgery and chemotherapy, individually or
in combination, continue to remain viable treatment modalities in clinical TNBC management.
However, recent studies have reported the discovery of novel receptors that could serve as targets
for the development of new anti-cancer therapeutics.

4.1 Surgery
Breast-conserving surgery (BCS) and mastectomy are primary candidates in TNBC
treatment. TNBC status, traditional clinicopathological variables, and patient preference
determine whether mastectomy or lumpectomy is the optimal treatment choice. A 2016
population-based study published in Lancet Oncology reported a higher survival in patients
subjected to BCS and radiotherapy as opposed to patients that underwent mastectomy (39).
Another study concluded that post BCS, the local recurrence rate was lower in TNBCs than other
breast cancer subtypes (40).

4.2 Chemotherapy
Cytotoxic chemotherapy remains the mainstay of TNBC treatment despite the
development of novel targeted therapies. Factors such as tumor size, lymph node status, grade,
and overall performance status are used to design individualized chemotherapy regimens for
TNBC patients (41). Several studies have underscored the benefit of using chemotherapeutic
drugs in the neoadjuvant, adjuvant, and metastatic treatment of TNBC. The administration of
8

neoadjuvant chemotherapy has consistently shown higher response rates (RR), thus promoting
improved long-term outcomes in TNBC. Additionally, a higher pathologic complete response
(pCR) related to neoadjuvant chemotherapy is observed in TNBCs when compared to luminal
non-TNBC subtypes (42). Although TNBCs are initially susceptible to chemotherapy, early
complete response (CR) often fails to correlate with OS. On the other hand, TNBC specific
adjuvant regimens that appear to be efficacious remain incompletely defined for both early
advanced stages of the disease. Currently, the chemotherapeutic strategies employed in the
management of TNBC are a) platinum compounds and taxanes targeting DNA repair complexes
and p53, b) anthracycline-based regimens targeting cell proliferation, and c) third-generation
chemotherapeutics using either dose-dense or metronomic polychemotherapy.

4.2.1 Platinum Salts
Due to the improvements in managing the non-specific toxicity of platinum agents, a
renewed interest in using DNA cross-linking agents (cisplatin and carboplatin) in TNBC treatment
has emerged. Further, the histological similarities between breast cancer type 1 susceptibility
(BRCA1)-mutated breast cancers and TNBCs, render platinum agents, a desirable therapeutic
strategy. The cytotoxicity of platinum agents is primarily exerted through the formation of mono
adducts, thus distorting the DNA double helix, to generate single and double-strand DNA breaks
(43). Preoperative TNBC therapy with platinum agents has yielded promising results. For
instance, a phase II study evaluating single-agent cisplatin in women with stage II or III TNBC
reported a pCR rate of 22%, with 36% of the patients demonstrating a Miller-Payne score of 4 or
5 which included both complete and near-complete responses (44). The success of platinum
agents in preoperative settings further bolstered the rationale behind their use in advanced TNBCs.
In the TBCRC009 trial, mTNBC patients received either cisplatin or carboplatin for three weeks.
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A median progression-free survival (PFS) of 89 days was observed, with 33% of patients
reporting a PFS less than six weeks, while another 33% had a PFS longer than six months (45).

4.2.2. Taxanes
Taxanes are a class of diterpenes that function through the disruption of microtubule
function (46). While taxanes remain an essential treatment modality in TNBCs, it does not
demonstrate any specific benefit over non-TNBCs (42). In an MD Anderson Cancer Center
(MDACC) study evaluating 1,118 patients treated with neoadjuvant anthracycline and taxane
combination therapy, the pCR rates were observed to be significantly higher in TNBC patients,
but both PFS and 3-year OS were substantially worse (22). The benefit of using taxanes in
adjuvant TNBC therapy has gained traction only recently. In the CALGB 9344/INT1048 trial,
randomized patients with node-positive operable breast cancer received three doxorubicin doses
followed by four paclitaxel cycles every three weeks. The addition of paclitaxel was associated
with significant improvements in the HER-2 negative, TNBC patient cohort (47). Abraxane, a
novel nanoparticle albumin-bound (nab) formulation of paclitaxel, demonstrated a significantly
improved PFS in mTNBC patients both alone and in combination with other chemotherapy (48).
However, the NSABP B28 trial comparing cyclophosphamide and doxorubicin with or without
paclitaxel found no significant difference in the relative risk of disease recurrence or OS based on
hormone receptor status (49). In the metastatic setting, several trials reported no specific benefit
of using taxanes in TNBC treatment. The CALGB9342 trial, which evaluated three different
paclitaxel doses for metastatic hormone receptor-positive tumors and mTNBCs, reported no
statistically significant difference in RR, but a significantly worse OS for TNBCs (50).
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4.2.3 Anthracyclines and Cyclophosphamides
Anthracyclines act through multiple mechanisms, including DNA intercalation,
topoisomerase-II mediated toxicity, reactive oxygen species (ROS) generation, and DNA adduct
formation, making them one of the most efficacious anti-cancer treatments ever developed (51).
On the other hand, cyclophosphamide promotes the formation of phosphoramide mustards, that
irreversibly crosslink with DNA to facilitate tumor cell apoptosis. In the study by Dees and
colleagues, the pathological

and

clinical RRs

for

neoadjuvant

anthracycline

and

cyclophosphamide (AC) combination chemotherapy were reported to be significantly higher in
TNBC patients than in other subtypes (52). Another study by Rouzier and collaborators reported
a pCR rate as high as 45%, following preoperative paclitaxel treatment combined with
fluorouracil, doxorubicin, and cyclophosphamide (53). The WSG 01 trial corroborated the benefit
of using adjuvant anthracycline therapy in young patients with TNBC. Most of the patients
showed a 5-year event-free survival rate (54). The anthracyclines doxorubicin, epirubicin, and
etoposide are commonly used in the treatment of mTNBC (55).

4.2.4 Anti-Metabolites
Anti-metabolites hinder cancer cell proliferation through the incorporation of
chemically altered nucleotides or the depletion of deoxynucleotides required for DNA replication.
In the clinical trial conducted by Kroman and collaborators, the addition of gemcitabine to
paclitaxel promoted an increase in RR (40.8% vs. 22.1%) and more prolonged survival (median
survival 18.5 vs. 15.8 months) in patients with advanced mTNBC (56). Further subgroup analysis
of two large randomized adjuvant capecitabine trials indicated that the addition of capecitabine to
anthracyclines and taxanes regimens was particularly effective in TNBC populations (57, 58).
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4.3 Novel Potential Therapies
As mentioned previously, TNBC patients demonstrate a relatively poorer disease
prognosis than other breast cancer subtypes. Extensive molecular and genetic profiling studies
have identified several different targetable mutations. In addition to the mutations in PIK3CA and
p53, other potential targets such as PTEN, INPP4B, KRAS, BRAF, EGFR, FGFR, IGFR1, KIT,
and MET have been explored (59). The recent characteri ation of TNBC s diverse subt pes and
molecular drivers has provided extensive insight into its heterogeneity. Further, it has led to the
evolution of in vitro and in vivo models that accurately recapitulate TNBC tumorigenesis, thus
providing the pre-clinical platforms required to develop novel therapeutic strategies.

4.3.1 Poly ADP-Ribose Polymerase Inhibitors
Some TNBCs resembling basal-like breast carcinomas frequently harbor defects in
DNA double-strand break repair due to BRCA-1 dysfunction. Such BRCA1-deficient tumors
exhibit high sensitivity to poly ADP-ribose polymerase (PARP) inhibition. PARP enzymes play
a pivotal role in the processing and repair of DNA breaks (60). In vitro, pre-clinical studies have
revealed that breast cancer cells lacking BRCA1/2 function exhibit a higher sensitivity to PARP
inhibitors (61). Olaparib and Iniparib are the PARP inhibitors showing the most potential. A
clinical trial using DNA-damaging agents and PARP inhibitors (olaparib) in conjunction has
shown promising results in BRCA1/2-deficient TNBC patients with advanced disease progression
(62, 63). Further, a randomized phase II study revealed that the clinical benefit rate, overall RR,
and PFS in mTNBC patients was significantly higher when Iniparib was added to carboplatin and
gemcitabine (64). A similar improvement in mTNBC patients was observed when Iniparib was
administered with gemcitabine and carboplatin (65).
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4.3.2 PI3K-AKT-mTOR Pathway Inhibitors
Owing to its multi-faceted role in promoting protein translation, tumor angiogenesis,
cancer cell proliferation, and migration, the mammalian target of rapamycin (mTOR) is a lucrative
anti-cancer therapeutic target (66). Currently, rapamycin and its analogs everolimus,
temsirolimus, and deforolimus are undergoing clinical evaluation in TNBC treatment (67). The
mesenchymal TNBC subtype, enriched in EMT and stem-cell like features, has demonstrated
some benefit from mTOR inhibition. Further, the MDA-MB-435 TNBC cell line harboring
phosphatase and tensin homolog (PTEN) deficiency has shown increased sensitivity to mTOR
inhibition (68), thus prompting the use of mTOR inhibitors in TNBC patients with PTEN loss
(13). Several reports have attributed cisplatin resistance to mTOR activation, a phenomenon
reversed by everolimus administration. Beuvink and colleagues revealed that the addition of
everolimus to cisplatin increased the loss of viability by 5- fold in vitro (69). Additionally, clinical
trials are also exploring the potential of targeting the AKT pathway in TNBC patients. For
instance, a phase II study reported a longer PFS and OS in 140 mTNBC patients upon the addition
of the AKT inhibitor capivasertib to paclitaxel (70).

4.3.3 Immune Checkpoint Inhibitors
The inception of immune checkpoint inhibitors (ICI) targeting programmed death-1
(PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4)
has drastically altered the treatment landscape for cancers like TNBC with a high mutational
burden (71). Several studies have suggested that the TNBC subtype is an attractive candidate for
cancer immunotherapy due to the presence of PD-1 positive TILs (tumor-infiltrating
lymphocytes) and higher rates of PD-L1 expression by the tumor and the immune cells (72, 73).
Pembrolizumab, a PD-1 inhibitor, was recently evaluated in a phase II, single-arm study in
patients with advanced TNBC (74). Results from the phase I trial evaluating the PD-L1 inhibitor
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atezolizumab in TNBC revealed an OR of 10% in a cohort of 112 patients, and a notable 11
responders were alive at two years (74). As monotherapy for advanced TNBCs, ICIs have resulted
in RRs ranging between 5% to 19%, with higher RRs based on PD-L1 status (75-77). However,
median PFS was observed to be only about 1.4 to 2.1 months. To date, atezolizumab is the only
FDA approved ICI used as first-line therapy in patients with advanced TNBC (78).

4.3.4 EGFR Inhibitors
Overexpression of EGFR is a common phenomenon observed in TNBC. This tyrosine
kinase receptor plays a crucial role in regulating PI3K AKT mTOR pathway and
ras/raf/mitogen-activated protein kinase/ERK kinase (RAS-MEK) pathway mediated tumor cell
proliferation, survival, and differentiation (79). Anti-cancer monoclonal antibodies (mAbs)
targeting dysregulated EGFR activity act through the following mechanisms: a) tumor cell death
through inhibition of receptor dimerization, inhibition of cell survival signaling and ligandreceptor blockade (80, 81), b) activating antigen-specific T cell immunity (82), c) complementmediated cytotoxicity (83). Cetuximab is a chimeric IgG1 mAb that binds and blocks ligandinduced EGFR in tumor cells (84). In pre-clinical studies, cetuximab effectively inhibited TNBC
tumor growth alone and in combination with chemotherapy (85). Further, in phase 2 trials, TNBC
patients receiving cetuximab combined with cisplatin had a significantly longer median PFS than
patients treated with cisplatin alone (86). When Lapatinib (an EGFR tyrosine kinase domain
inhibitor) was combined with rapamycin, they produced a gradual dose-dependent growth
inhibition in MDA-MB-231 and MDA-MB-468 TNBC cell lines in vitro (87).

4.3.5 Angiogenesis Inhibitors
Tumor-specific vascular endothelial growth factor (VEGF) expression is observed to
be significantly higher in TNBCs when compared to non-TNBC presentations. The anti-VEGF
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agent, Bevacizumab (Avastin®), has received controversial attention despite showing potential in
several clinical trials. However, multiple Phase III trials are investigating the efficacy of
bevacizumab in the mTNBC setting (88). In the E2100 trial, the addition of bevacizumab to
paclitaxel, doubled the median PFS (5.3 versus 10.6 months), while reducing the risk of
progression by 51% in first-line mTNBC patients (89). The AVADO trial demonstrated a 47%
reduction in mTNBC disease progression when bevacizumab was added to docetaxel (90). In the
neoadjuvant setting, the GeparQuinto trial studying the effect of combining bevacizumab with
anthracycline taxane chemotherapy, demonstrated a statistically significant improvement in pCR
rates (N = 663; 39.3% versus 27.9%, P = 0.003) for patients receiving bevacizumab compared
with chemotherapy (91).

5. Mechanisms of Triple-Negative Breast Cancer Chemoresistance
Despite numerous advances in cancer therapeutics, chemotherapy remains the mainstay
in systemic TNBC treatment. Neither anti-HER-2 agents nor hormonal therapies are efficacious
owing to the absence of their targets in the TNBC setting (92). Cytotoxic chemotherapy induces
cancer cell death primarily through apoptosis. As depicted in Figure 1, although chemotherapy
administration initially promotes tumor regression, chemoresistance is eventual as tumor cells
evade drug exposure by turning to alternative cellular fates, thus promoting metastatic recurrence
(41). The findings below highlight some of the mechanisms of TNBC chemoresistance.
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Figure 1: Chemoresistance promotes metastatic recurrence. Primary tumor cells that survive
chemotherapy administration acquire an invasive phenotype and undergo metastatic
dissemination to distant organs.

5.1 ATP-Binding Cassette Transporters
Transporter-mediated drug efflux is one of the most extensively validated mechanisms
of chemoresistance (93). ATP-binding cassette (ABC) transporters utilize ATP binding to
translocate various substrates, including anti-cancer drugs across the cell membrane. The three
ABC transporters most frequently upregulated in TNBCs are a) multidrug-resistant protein-1
(MRP-1), which confers resistance against vinca alkaloids, high-dose methotrexate, and
anthracyclines. b) P-glycoprotein (MDR-1), which effluxes a broad spectrum of taxanes such as
paclitaxel out of cancer cells, and c) breast cancer resistance protein (ABCG-2), which pumps out
drugs such as doxorubicin (94).

5.2 Mutations in DNA Replication and Mismatch Repair Enzymes
DNA damage is the primary mechanism of action of most conventional
chemotherapeutics. Several studies have suggested chemoresistance to be a result of aberrant
DNA damage repair due to altered DNA mismatch repair enzyme function. For instance,
chemoresistance against anthracyclines and epipodophyllotoxins was attributed to mutations in
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the critical DNA replication and repair enzyme topoisomerase II (95, 96). The study by Fedier
and colleagues further confirmed that the resistance to topoisomerase II inhibitors was due to
inhibited expression of DNA-mismatch repair proteins (97).

5.3 Tumor Dormancy
Following chemotherapy administration, chemoresistant tumor cells sometimes exist
in a dormant state for several years before resuming proliferation. These dormant cancer cells
adapt by entering quiescence and undergo alterations in their signaling pathways, protein
expression, and modulation to survive chemotherapy-induced cytotoxic stress. Post-treatment,
these cells re-initiate tumor growth, which promotes disease recurrence after an initial response.
Tumor dormancy may be established through chemotherapy-induced cellular senescence (CIS),
which results in permanent cell cycle arrest without cell death. Although this stress response
reduces tumor growth, cancer cells often exit CIS and regain proliferative capacity. The effect of
chemotherapy on the senescence-linked signaling via p53, p16lnk4a, p21Waf1/Cip1, and
p27Kip1, resulting in tumor dormancy, continues to be a hotly debated topic.

5.4 Epithelial to Mesenchymal Transition
Several recent studies suggest the involvement of EMT in antagonizing
chemosensitivity in several cancers, including TNBC. As discussed previously, EMT entails the
dynamic transition promoting the acquisition of invasiveness, resistance to apoptotic stimuli,
motility, and a mesenchymal phenotype by epithelial cancer cells (98). Aberrant expression of the
Snail family of transcription factors not only initiates EMT but also confers resistance to apoptosis
induced by genotoxic stress in MDA-MB-468 and MDA-MB-231 TNBC cell lines in vitro (99).
Compelling evidence also demonstrated that the EMT inducer Twist up-regulated ABC
transporter expression, which leads to multidrug resistance in human breast cancer cell lines (100,
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101). Twist is implicated in the activation of the -catenin signaling pathway and AKT pathways,
known to reinforce the loss of chemosensitivity (102).

5.5 Cancer Stem Cells
Growing evidence indicates that cancer recurrence is caused by multipotent selfrenewing cancer-initiating cells, commonly referred to as cancer stem cells (CSCs). The CSC
paradigm has emerged based on the notion that some, but not all, cancer cells have the potential
to recapitulate the phenotypic diversity of the original tumor upon transplantation. The biological
features of CSCs largely overlap with those of drug-resistant cancer cells. Recent studies suggest
that upon exposure to conventional chemotherapy, TNBC biopsies demonstrate an increase in
RNA transcripts of genes associated with the CSC phenotype. For instance, treatment with
taxanes like paclitaxel significantly increased TGF- signaling and other CSC properties in
several TNBC cell lines and mouse xenografts (103). The TGF- c tokine famil and its receptors
are often overexpressed in CSCs. Through TGF- induced EMT, CSCs promote TNBC relapse
(104). Another study reported elevated expression and transcriptional activity of hypoxiainducible factors (HIFs) post gemcitabine administration in TNBC cell lines. This eventually
promoted CSC enrichment through upregulated IL-6 and IL-8 signaling (105).

5.6 Hypoxia
A prominent feature of the tumor milieu is hypoxia, where an inadequate supply of
oxygen occurs due to tumor cells outgrowing their vasculature (106). Clinically, TNBC tumors
are found to be more hypoxic than their non-TNBC counterparts (41). By varying the oxygen
levels within the TME, hypoxia propagates a chemoresistance phenotype that is accompanied by
tumor aggressiveness and metastatic dissemination. Hypoxia promotes the development of an
acidic TME, thus compromising chemotherapy drug uptake (107). Further, hypoxia protects
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tumor cells against immune surveillance by acting as a barrier to immune effector cells (108).
Additionally, hypoxia stimulates cellular adaptations including; a) upregulated ABC transporter
expression, b) decreased proliferation, c) autophagy induction, d) upregulation of pro-angiogenic
factors, e) enhanced genetic instability and subsequent clonal selection of aggressive phenotypes
and f) E-cadherin repression which furthers cancer progression (109).

5.7 Cell-Signaling Pathways
5.7.1 NF- B Pathway
A crucial regulator of carcinogenesis, the NF- B signaling pathwa , inhibits apoptosis,
controls the inflammatory response, and angiogenesis. Hyperactivation of the NF- B pathwa is
often implicated in TNBC progression and poor prognosis. In 2018, Huang and colleagues
demonstrated that doxorubicin administration stimulated the overexpression of pleiotrophin
(PTN) and its cognate receptor protein tyrosine phosphatase zeta (PTPRZ1) in several TNBC cell
lines. The upregulated PTN/ PTPRZ1 signaling axis subsequently promoted chemoresistance
evolution through the activation of the NF- B signaling pathwa in vitro (110). Alternatively, that
NF- B signaling can also be up-regulated by hypoxia (111).

5.7.2 PTEN and PI3K-AKT-mTOR Pathway
PI3K-AKT-mTOR (PAM) pathway is a critical mechanism governing cancer cell
survival, growth, proliferation, and motility. Frequent up-regulation of the PAM pathway
accounts for the adverse prognosis, aggressive nature, and poor outcome observed in most TNBCs
(112). Further, the skewed expression of the PAM pathway components is also associated with
TNBC chemoresistance (113). Additionall , the PAM pathwa s AKT induces HIF-1, which
plays a notable role in chemoresistance onset (114).
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5.7.3 JAK/STAT pathway
Aberrant JAK/STAT signaling plays a pivotal role in mediating the metastatic cascade
(115). Genetic profiling of chemotherapy-refractory TNBCs revealed a pro-inflammatory gene
signature due to JAK/STAT pathway extracellular ligand (Interleukin (IL)-6/IL-8) overexpression
(116). STAT-3, which is a downstream component of the JAK/STAT signaling axis, is frequently
overexpressed in TNBC. STAT-3 interacts with NF- B to promote chemoresistance in TNBC
(117). Moreover, through the up-regulation of both HIF-1 and ABC transporter expression,
STAT-3 also induces hypoxia-mediated chemoresistance in TNBC (118).

5.7.4 TGF- Pa h a
While the TGF-

signaling pathwa

is s non mous with EMT, proliferation,

angiogenesis, and subsequent metastatic progression, it is mostly recognized for regulating breast
CSCs (119). Post chemotherapy administration in a TNBC setting, elevations in the TGFsignaling was observed (103). Further, the exposure of several TNBC cell lines to TGFpromoted EMT and the acquisition of CSC properties, including chemoresistance (120).

5.7.5 Wn / -Catenin Pathway
Wnt signaling is predominantly associated with tumor initiation, stemness, and
metastatic dissemination (121). Several studies have highlighted the pivotal role pla ed b Wnt/ catenin signaling in promoting the tumorigenic behavior associated with the TNBC subtype, For
instance, TNBC patients with aberrant Wnt/ -catenin signaling were reported to be more
susceptible to metastatic progression, especially to the brain and lung (122). In another seminal
study, the Wnt signaling was identified to be vital for development, enhanced proliferation,
increased migration, and chemotherapy resistance in TNBCs (123). Further,

-catenin was

demonstrated to have a synergistic effect with Nek2B on chemotherapy resistance in TNBC (124).
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Other constituents of the Wnt/ -catenin pathway, such as FZD-8 (a member of the Frizzled
receptor family) was overexpressed in TNBC and linked to TNBC chemoresistance following
neoadjuvant chemotherapy (125).

5.8 Receptor Tyrosine Kinases
The PAM and JAK/STAT signaling pathways are employed by numerous growth
factors to mediate tumorigenesis. The upstream regulators of these pathways, namely the insulinlike growth factor-1 receptor (IGF-1R) and EGFR, are often implicated in TNBC
chemoresistance. EGFR expression is markedly higher in TNBCs, making it a prominent TNBC
hallmark. Several studies have confirmed the correlation between EGFR amplification and
expression with worse outcome in TNBC (126, 127). Via the regulation of ABCG-2 expression
and function, the EGFR pathway is observed to promote chemoresistance in TNBC cell line and
xenograft models (128). IGF-1R is a transmembrane receptor overexpressed in TNBCs and is
frequently associated with poor survival (129). Insulin-like growth factors (IGFs) bind to their
receptors, activate the downstream signaling cascade to promote chemoresistance evolution via
ABC transporter expression, and apoptosis inhibition (130). Through its interaction with the
Wnt/ -catenin pathway, IGF-1 enhances CSC growth and self-renewal potential (131).

6. Tumor-Targeting Peptides
The efficacy of most anti-cancer agents is often hindered by its inability to target,
penetrate cellular membranes, and eventually localize within the tumor. Unlike standard
chemotherapeutic agents that induce non-specific cytotoxicity, targeted therapies are often
cytostatic. Their deliberate interaction with molecular targets e pressed on the cancer cell
surface inhibits cancer growth and progression (132). Targeted therapies like nanoparticles or
antibodies possess a high molecular weight (MW), high affinity, and low diffusion coefficient
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that impede tumor penetrability (133). On the other hand, smaller MW entities like peptides offer
fundamental advantages, including easy synthesis, higher cell membrane penetration, and lesser
immunogenicity (134).
Tumor-targeting peptides (TTPs) are two-dimensional linear chain amino acid
sequences (135), modified to either directly target cancer cell surface receptors or act as
chaperones delivering cytotoxic drugs to the TME, tumor vasculature, and cancer cells. Targeting
and concentrating these peptides to specific cancer tissue components is achieved via tumorspecific biomarkers. TTPs can be coupled with either cargo or an apoptotic domain. The homing
domain can be identified through antibody-based screens, bio-panning of phage-displayed peptide
libraries, identified in silico using random generation algorithms, or through imitation of protein
fragments known to bind to the receptor of interest (135).

6.1 Phage Display Screening for the Isolation of Tumor-Targeting Peptides
In 1985, Nobel laureate George Smith demonstrated that filamentous phages could be
genetically modified to display peptides as fusions on the virus capsid protein (136). This opened
the possibility of isolating phage-displayed peptides by selecting for those with the highest
binding affinity to the desired target. As shown in Figure 2. below, The multivalent display of
foreign polypeptides is achieved by cloning the peptide encoding combinatorial DNA sequences
into the M13 phage s pIII or pVIII gene. Each phage-displayed peptide is designed as a linear
chain of variable random amino acid residues (Xn, 6 n 12), resulting in the generation of phagedisplayed peptide libraries with complexities up to a 1013 magnitude. To reduce conformers and
improve affinity, the random sequences are enclosed within two cysteine residues to generate
cysteine-to-cysteine disulfide cyclized phage-peptide libraries (137).
The isolation of phage-displayed peptides homing to the target of interest is carried out
via an affinity selection process, alternatively known as bio-panning. Homogenous in situ phage
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library bio-panning using immobilized antigens can be used to isolate peptides with high affinity
and specificity (138). However, to facilitate the identification of peptides that mimic naturally
occurring receptor ligands or target heterogeneous environmental conditions, screens were
performed in vitro (139), in vivo (140), ex vivo (141), and inpatient (142) settings.

Figure 2. A diagrammatic representation of M13 bacteriophage. Each bacteriophage is 1,000
nm in length and 5 nm wide. The peptides are displayed as fusions on the pIII minor coat protein.

6.2 Tumor-Targeting Peptides Specific to the TME
Owing to its indispensable role in carcinogenesis, the TME serves as an alternative
target for future therapies. Due to their low production cost, high specificity, and tumor
penetrability, there has been a renewed interest in using phage display technology to identify
peptides that efficiently target the TME. The findings below highlight some TTPs targeting
various stromal constituents of the TME.

6.2.1

Peptides Targeting Tumor Vasculature
The tumor vasculature, with its consistently high angiogenic marker (i.e., VEGF

receptor (VEGFR) and integrins) e pression, pronounced h po ic regions, leak

nature, and

pivotal role in tumorigenesis, serves as an attractive therapeutic target. A prominent example of
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a tumor vasculature specific therap is the RGD peptide. Isolated using in vivo phage display
technology in prostate tumor-bearing mice, the cyclic RGD peptide (sequence: CDCRGDCFC)
was identified to bind with

v-3 and

v-5 integrins over-expressed on tumor blood vessels

(143, 144). Subsequently, another pioneering study by Arap and colleagues led to the discovery
of the NGR motif bearing c clic peptides (sequence: CNRGC) that targeted tumor vasculature
in melanoma, breast carcinoma and Kaposi s sarcoma (145). This peptide homed to the
aminopeptidase N (APN/CD13) receptors detected in tumor vasculature (146).

6.2.2

Peptides targeting Extra-Cellular Matrix
The extracellular matrix (ECM) is composed of immensely diverse components,

including fibronectins, tenascin C (TNC), collagen, and connective tissue growth factor, to name
a few. Tumor-associated fibronectin (TAF) plays a vital role in promoting cancer cell survival,
proliferation, invasiveness, and metastatic dissemination (147). During tumor driven ECM
remodeling, TAF undergoes alternative splicing, which results in extra domains A and B (EDA
and EDB). Through in situ phage library bio-panning, an EDB binding scaffold-like peptide
named APTEDB was identified (138). This peptide was further modified to a targeting ligand
that could be conjugated with anti-cancer drugs to reduce systemic toxicity, deliver cargo,
including siRNA, oligonucleotides, and imaging probes (148, 149).
The TNC glycoprotein mediates the assembly of other ECM molecules and plays a part
in mediating cell adhesion, permeation, migration, and differentiation. TNC is specifically
associated with several solid tumor malignancies, including breast, colon, and oral cavity (150).
This led to the isolation of a TNC targeting peptide (sequence: FHKHKSPALSPV) that
selectively bound to TNC in both xenograft mouse tissues and patient tumors and acted through
the reduction of TNC-induced cell rounding and migration (138). More recently, Yeow and
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collaborators ingeniously tackled tumor ECM targeting by conducting the first three rounds of
bio-panning in MatrigelTM in vitro and the last round in vivo. Following the four rounds, a
disulfide cyclized peptide (sequence: CSGRRSSKC) that exclusively homed to laminin-nidogen
receptor complexes of the ECM was isolated (151).

6.2.3

Peptides targeting Matrix Metalloproteases
Abrogated ECM remodeling triggers the release of biophysical and biochemical cues

that set the events of neoplastic evolution in motion. MMPs are one of the most studied ECM
remodeling enzymes due to their up-regulation in the TME and roles in angiogenesis regulation,
tumor cell migration, and invasion. Despite being secreted proteins, MMP-2 and MMP-9 mediate
phage homing by binding to integrins expressed by tumor vasculature. Based on this principle,
peptides targeting the gelatinase members of the MMP family (sequences: CRRHWGFEFC and
CTTHWVGLMS) and subsequently inhibiting MMP-2 and MMP-9 activity were discovered
(152). In 2019, Bicycle therapeutics pioneered in vitro phage display technology to develop
BT1718, a peptide-drug conjugate targeting the ECM enzyme MMP-14. This drug is currently
undergoing Phase I clinical trials in patients with advanced solid tumors (133).

6.2.4

Peptides targeting Cancer-Associated Fibroblasts
Within the TME, cancer-associated fibroblasts (CAFs) are often found to reside within

the proximity of tumor cells. Unlike tumor cells that express diverse cell surface markers, CAFs
predominantly overexpress specific proteins, including fibroblast-activated protein-alpha (FAP) and alpha-smooth muscle actin ( -SMA) (153). Thus, CAF targeting may be an alternative
strategy to improve anti-tumor efficacy. In a seminal study combining in vivo phage display and
the PHASTpep software, two peptides (sequences: APPIMSV and HTTIPKV) targeting CAFs
were identified (154). The peptides selectivel bound to onl
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-SMA positive pancreatic CAFs

in mice. Several studies have reported that the CAFs within the TME of colon, breast, and prostate
were carcinomas dependent on the urokinase plasminogen activator (uPA) receptor signaling axis
to mediate the events implicated in early tumor development. This prompted the isolation of a
peptide (sequence: LWXXAr (Ar = Y, W, F, H) XFXXYLW) that acted as a potent antagonist
against the uPA receptor (155).

6.2.5

Peptides targeting Tumor-Associated Macrophages
Derived from circulating monocytes within the TME, tumor-associated macrophages

(TAMs) are specified as a separate myeloid population of the TME. Tumor-secreted cytokines
(IL-4 or M-CSF) mediate macrophage polarization into anti-inflammatory M2-skewed TAMs that
promote tumor angiogenesis, immunosuppression, and neoplastic transformation (156). M2skewed TAMs traverse the TME s comple milieu with either the aid of collagen-interacting
proteins, including collagenases, MMP-9, and mannose receptors (CD206/MRC-1) or through
tumor vasculature via VEGF secretion (157). The in vitro phage-displayed peptide library biopanning

performed

by

Cieslewicz

and

collaborators

yielded

M2Pep

(sequence:

YEQDPWGVKWWY), which selectively targeted M2-skewed mouse TAMs in mouse colon
carcinoma tumors (158). To improve its affinity, the authors synthesized a tetravalent version of
the peptide, which coupled was to a C-terminal cysteine on a maleimide scaffold. This peptide
was then conjugated with a pro-apoptotic domain, which augmented its toxicity towards M2
TAMs (158). In 2017, in vivo phage display in metastatic breast cancer-bearing mice led to the
identification of a CD206-binding peptide termed mUNO (159). The internalization of mUNO by
M2 TAMs was mediated through the minimal binding CSPGAK sequence motif present in all
CD206-binding collagens. Interestingly, the mUNO peptide also binds to human recombinant
CD206, indicating future therapeutic potential in cancer patients (159).
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6.3 Tumor-Targeting Peptides Specific to Overexpressed Tumor Receptors
Post administration, anti-cancer therapies often modulate the expression of cell-surface
receptors implicated in carcinogenesis. Agents such as antibodies, peptides, or small molecule
inhibitors, can serve to inhibit the receptor s downstream activit b directl binding to them,
thus halting cancer progression. In the following section, a few prominently over-expressed
receptors used in cancer cell-specific targeting have been discussed.

6.3.1

Peptides Targeting EGFR
Through its complex signaling cascade, EGFR modulates several events implicated in

carcinogenesis, including cancer cell survival, proliferation, differentiation, adhesion, and
migration. In 2014, Wang, Zho, and Joshi were awarded an international patent (Patent No.
WO2016029125A1) for 17 EGFR-specific peptides identified through in situ phage library
screening of Ph.D.-7 heptapeptide and Ph.D.-12 decapeptide random libraries from New England
Biolabs (160). Li and colleagues are credited with isolating the prominent GE11 peptide,
internalized preferentially by both EGFR overexpressing cancer cells in vitro and tumor
xenografts in vivo (161). Another group identified two short peptides (sequences: SYPIPDT and
HTSDQTN) via an in vitro cell-based subtractive bio-panning approach in EGFR overexpressing
A-431 cells. These peptides effectively inhibited EGF-induced phosphorylation of EGFR in a
concentration-dependent manner (162).

6.3.2

Peptides Targeting VEGFR
VEGFR belongs to the VEGFR receptor family (VEGFR 1, 2, 3, and neuropilin 1). The

overexpression of VEGFR and its cognate VEGF ligand is observed in several malignancies (163165). To identify novel ligands specific to VEGFR-3, Qin and coworkers used phage-displayed
peptide library screening to isolate the peptide P1 (sequence: CSDXXHXWC, where X is any
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amino acid) which bound to all VEGFR-3 positive tumor cells with a high degree specificity
(166). In another study, using the novel BRASIL method, Giordano and colleagues sorted for cellsurface binding peptides based on differential centrifugation. They isolated 21 phage-displayed
peptide clones that bound to VEGF-stimulated HUVEC cells (167).

6.3.3

Peptides Targeting Interleukin 11 Alpha Receptor
Upon up-regulated expression, IL-11 confers several tumor intrinsic hallmarks to

neoplastic cells. An integral member of the IL-6 family of cytokines, it dictates the progression
of the metastatic cascade via downstream JAK/ STAT-3 signaling pathway activation (168).
Pasqualini and colleagues first explored the potential of using IL-11 R as an anti-tumor target via
in vivo bio-panning of a 7-mer library in chemotherapy-refractory B cell malignancy bearing
patient (142). In a companion study, the authors isolated a phage clone (sequence:
CGRRAGGSC) that bound to IL-11 R overexpressed in the prostate, which was further validated
in prostate tumor-bearing mice and human prostate cancer tissue samples (169).When conjugated
with a pro-apoptotic moiety, this peptide also demonstrated acute cytotoxicity on cultured prostate
cancer cells (165).

6.3.4

Peptides Targeting Folate Receptor Alpha
Folate receptor-alpha (FR ) overe pression often co-relates with high tumor grade,

stage, malignancy, and aggressiveness (170), thus serving as a potential target for tumor therapy
and diagnosis. Xing and coworkers isolated the FR

specific C7 peptide (sequence:

MHTAPGWGYRLS) by screening a Ph.D.-12 phage library displaying random dodecapeptides
in an ovarian cancer mouse model. The C7 peptide was further validated outside the phage
context, through in vivo phage homing experiments and fluorescence imaging (171).
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6.3.5

Peptides Targeting PDGFR beta
A transmembrane glycoprotein in the receptor tyrosine kinase family, PDGFR-beta

(PDGFR ), is implicated in cancer cell proliferation, differentiation, and development (172).
Owing to its upregulation in a variety of solid tumors, this receptor represents an attractive target
in the treatment and molecular imaging of oncological diseases. PDGFR-P1 (sequence:
IPLPPPSRPFFKY-NH2) is a s nthetic peptide designed to bind to PDGFR overe pressing cells
in vitro. In vivo biodistribution studies in the BxPC3 tumor mouse model revealed a high
accumulation of PDGFR-P1peptide in BxPC3 tumors than in normal organs (173).

6.4 Design of Tumor-Specific Hunter-Killer Peptides
A unique feature of anti-microbial peptides (AMPs) is the amphipathic -helix, which
grants its membrane permeabilization and resultant cytotoxic potential. The synthetic
(KLAKLAK)2 moiety, which mimics AMP features and demonstrates significant anti-microbial
activity, was generated based on this principle. The (KLAKLAK)2 moiety is highly selective to
the anionic membranes of prokaryotes and is poorly permeabilized by eukaryotic plasma
membranes. To promote tumor cell internalization, the (KLAKLAK)2 moiety is fused with TTPs
to generate hunter-killer peptides that act through mitochondrial disruption (174). For instance,
the hunter-killer R7- (KLAKLAK)2 peptide consisting of the homing domain (R7 or RRRRRRR)
shows increased cellular uptake and efficient apoptosis in several tumor cell lines and human
xenografts (175). Along the same principles, the NH2-terminus of TCTP (human translationally
controlled tumor protein) was fused to the (KLAKLAK)2 moiety resulting in the hunter-killer
TCTP-(KLAKLAK)2 peptide. This peptide promoted the regression of lung carcinomas implanted
in mice (176). Our own group has generated a proteolysis-resistant targeted hunter-killer peptide
D-WAT. This peptide is composed of a cyclic domain CSWKYWFGEC homing to adipose
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stromal cells and pro-apoptotic domain (KFAKFAK)2 (177). The addition of the (KFAKFAK)2
moiety was observed to improve the cytoablative properties of D-WAT. The above examples
underscore the potential use of TTPs fused to a cytotoxic peptide, to produce a highly efficacious,
tumor cell ablating complex.

30

Chapter 2: Statement of Objective
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1. Knowledge Gap
An insurmountable challenge encountered in the clinical management of TNBCs is metastatic
progression. Metastatic dissemination continues to be a major perpetrator of TNBC patient
mortality. Owing to the unresponsiveness of TNBCs to hormone therapy, chemotherapy remains
a mainstay in mTNBC treatment. Despite chemotherapy eliciting a brief response in the tumors,
drug resistance gradually develops. Several studies suggest that chemotherapy appears to select
for cells with CSC properties that drive cancer toward more aggressive stages (178). There are no
bio-markers specific to chemoresistant metastatic tumor cells. Moreover, there is a dearth of drugs
available to selectively target them. Therefore, it is imperative to develop novel targeted therapies
to ablate these stubborn tumor cell populations. The isolation and development of peptides
selectively targeting these chemoresistant metastatic tumor cells would be pivotal for cancer
medicine, as they would enable targeting the mortality-responsible cell population with minimal
side effects. This rationale encouraged us to formulate the following hypothesis.

2. Hypothesis
Metastatic chemoresistant TNBC cells display novel cell surface biomarkers, which can be used
in the identification of new compounds homing to these unique cell populations and specifically
ablating them.

3. Aims and Experimental Approach
Aim 1: Identify phage-displayed peptides homing to chemoresistant metastatic tumor cells.
Experimental Approach
Perform an in vivo phage-displayed peptide library screen in a spontaneous TNBC lung
metastasis model to isolate phage-displayed peptide candidates homing to metastatic tumor
cells.
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Compare the homing of the phage-displayed peptide candidates between vehicle control and
cisplatin-treated in vitro and in vivo models.
Identify the most enriched breast lung metastasis peptide (BLMP) candidate.

Aim 2: Conversion of phage-displayed peptides into hunter-killer peptides that ablate metastatic
tumor cells in vitro and in vivo
Experimental Approach
Validation of the chemically synthesized hunter-killer peptide candidates in vitro.
In vivo studies to validate the ability of hunter-killer peptides to ablate TNBC pulmonary
metastases.

4. Graphical Abstract

Figure 3: Schematic depiction of the study
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Chapter 3: Materials & Methods
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1. Cell Lines and Cell Culture
Murine

fibroblast

3T3L1

(ATCC® CRL-1658 ), murine

melanoma

B16-F10

(ATCC® CRL-6475 ), murine mammary breast adenocarcinoma E0771 (ATCC® CRL-2755 ) cell
lines were obtained from the ATCC (Manassas, VA). The human mammary adenocarcinoma
MDA-MB-231 cell line was kindl provided b Dr. Wenliang Li s lab (IMM-UTHealth, Houston,
TX). The mammary adenocarcinoma murine 4T1 cell line with dual luciferase and mCherry
expression (4T1 - Luc+ mCherry+) was kindl provided b Dr. Sendurai A. Mani s lab (MDACC,
Houston, TX). The murine mCherry labeled 4T1.2 (4T1.2 - mCherry+) breast tumor cells (derived
from spontaneous adenocarcinoma in a Balb/cfC3H mouse) was kindly provided by Dr. Naoto
Ueno s lab (MDACC, Houston, TX). It s cisplatin-resistant cell lineage, 4T1.2/CTX, was
generated with a biweekly treatment of cisplatin (Tocris Biosciences, Minneapolis, MN;
180ng/mL) to maintain consistent drug resistance. The cell lines were cultured in DMEM media
(Hyclone Laboratories Inc., Logan, UT) supplemented with 1% penicillin-streptomycin (Gibco)
and 10% FBS (Atlas Biologicals, Fort Collins, CO). All cell lines were cultured on plastic plates
maintained at 37ºC and 5% CO2. Sub-culturing was performed at 70% cell confluency. Adherent
cells were washed with 1X PBS (Phosphate-Buffered Saline) solution (Fisher Scientific,
Waltham, MA) and detached with 0.25% trypsin-EDTA (Gibco) and then sub-cultured.

2. Murine Model of Experimental Lung Metastasis
All mouse experiments were performed in accordance with the bioethical principles
adopted by the Institutional Animal Care and Use Committees of UTHealth and MDACC. Female
C57BL/6 mice (Jackson, Bar Harbor, ME) were aged eight weeks prior to experimental
manipulation. The mice were anesthetized using tribromoethanol (150mg/kg) administered
through intraperitoneal injections. Murine melanoma B16-F10 cells (100,000 cells suspended in
100 l DMEM) were injected into the mice intravenousl . Following this procedure, the mice were
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kept warm under a heat lamp and monitored until recovery. Upon resuming mobility, the mice
were housed back in their cages. Ten days post tumor implantation; the mice were randomized
into vehicle and chemotherapy-treated cohorts. The mice were administered either vehicle (1X
PBS solution) or cisplatin (Tocris Biosciences; 2.5mg/kg) retro-orbitally once a week for three
weeks. Upon exhibiting distress, the mice were euthanized, and their organs (brain, spleen, liver,
kidney, and lung) surgically resected. After excision, the tissues were fixed in 10% neutralbuffered formalin (Thermo Fisher Scientific, Waltham, MA) for histopathological analysis.

3. Orthotopic Murine Model of Spontaneous Lung Metastasis
Female Balb/c mice (stock 000651, Jackson) were six weeks old at the start of the
experiment. Prior to cell injection, the animals were anesthetized through 2-4% isoflurane (Fisher
Scientific) inhalation. The site of tumor implantation was prepped with 70% ethanol solution and
shaved with hair clippers. 4T1-Luc+ mCherry+ (20,000 cells suspended in 20 l DMEM) were
subcutaneously injected into the mammary gland of the syngeneic Balb/c mice. The correct
injection of cancer cells was validated through the visual confirmation of fat pad swelling. Once
palpable, the growing primary tumors were measured biweekly with calipers with tumor volume
calculated using the (length x width2)/2 formula. After the tumor volumes reached ~ 200mm3, the
mice were randomized into two cohorts, vehicle and chemotherapy-treated, respectively. The
mice were administered either vehicle (1X PBS) or cisplatin (Tocris Biosciences; 2.5mg/kg) retroorbitally once a week for three weeks. Multiple row t-tests were performed to account for the
differences observed in tumor volume between the two groups. Upon exhibiting adverse effects
such as labored breathing or ulcerated tumors, the mice were humanely euthanized. This was
followed by surgical resection of organs (brain, spleen, liver, kidney, and lung) and tumors. After
excision, the tissues were then fixed in 10% neutral-buffered formalin.
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4. Non-Invasive Bioluminescence Imaging to Monitor Metastatic Progression In Vivo
4T1 Pulmonary metastases bearing mice were injected intraperitoneally with Dluciferin (Promega, Madison, WI; 150 mg/kg) and anestheti ed 9 minutes before the peak
luciferin uptake time (according to manufacturer s procedures) with 5% isoflurane. At the optimal
imaging time, the mice were transferred to the imaging chamber (IVIS SPECTRUM, PerkinElmer
Inc., Boston, MA) with their mouths and noses firmly set within the anesthetic tubing maintained
at 2% isoflurane until BLI was completed. In the fat pad spontaneous metastasis model, weekly in
vivo bioluminescence imaging BLI was initiated at the time of tumor implantation. Due to
differences in tumor burden, an autoexposure (1 second 1.5 minutes) was used for each mouse to
account for any variabilities in the bioluminescence signal. BLI imaging of the primary tumors
was performed in the following setting: emission filter: open, f/stop: 1, binning: medium,
1 scan/minute, e posure time: 1 15 second. While imaging metastatic lesions in the thoracic
cavity, bleed-over from the implantation site was avoided by masking the primary tumor/injection
site with an X-ray sheet encased in aluminum foil. Metastatic burden was then evaluated by
drawing a standard circular ROI (same size over all the time points) over the lung region.
Luminescence was expressed as photons/sec/ROI minus background luminescence for a region
of similar size. Bioluminescent signals were quantified to radiance intensity using Living Image
3.0 (Caliper Life Sciences, Almeda, CA).

5. In-situ Lung Perfusion and Fixation
The animals bearing pulmonary metastases were anesthetized using tribromoethanol
(150mg/kg) administered through intraperitoneal injections. When the mice's reflexes were no
longer observed, the mice were splayed on a Styrofoam board with their limbs secured in position
with push pins. The fur was wet with 70% ethanol to slick the hairs down. The chest cavity was
opened with surgical scissors, and a V shaped incision was made from the sternum ape through
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the ribs to the upper left and right shoulder. This was followed by cutting the vena cava caudalis
underneath the liver. Using a 20 mL syringe equipped with a 21G needle, 15mL 1X PBS was
slowly injected into the right ventricle of the beating heart until the lungs were inflated, and the
heart stopped beating (asystole). Using forceps, the heart and lungs were pulled out as one unit
by firmly grasping the lung hilus directly above the heart. The heart was separated from the lungs
carefully by pulling the heart with forceps, and by transecting connective tissue ligaments and
blood vessels. The lungs were then fixed in 10% neutral-buffered formalin.

6. Enumerating Pulmonary Metastasis in Mice
The lungs bearing pulmonary metastases were fixed in 10% neutral-buffered formalin
until the metastatic nodules were bleached to amelanotic gray/white nodules. Using forceps, the
fixed lungs were pried apart into individual lobes. At 10X magnification, the tumor nodules on
each lobe were enumerated blindly beneath a dissecting microscope. For consistency between the
mice, the foci number on the lobe surface was first counted, and then the lobe was inverted. Doing
each of the four lobes individually allowed for more accuracy in counting. The average number
of nodules for all mice within both treatment groups was determined.

7. In Vivo Phage-Peptide Library Bio-panning for Lung Metastases Targeting Peptides
7.1

Round 1 of In Vivo Phage-Displayed Peptide Library Bio-panning
Phage-displayed peptides were selected from fUSE5 phage-peptide libraries, which

were kindly provided by Dr. Erkki Koivunen (University of Helsinki, Finland). Library
amplification was conducted as described previously (179). Phage transducing units (TU) were
determined through titration with K91 Escherichia coli. A mouse bearing 4T1 pulmonary
metastases from the chemotherapy-treated cohort was anesthetized through 2-4 % isoflurane
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inhalation. A 1010 TU mixture of cyclic CX7C and CX8C (C: disulfide-bonded cysteines; X: any
amino acid) phage-displayed peptide libraries suspended in 1X PBS was injected intravenously
and allowed to circulate for 3 hours. The mouse was perfused with 15mL of 1X PBS solution as
described previously in Section 5, to facilitate phage elimination from normal vasculature and
other non-lung metastasis specific antigens. The mouse was euthanized, and its organs (lungs,
liver, kidney, primary tumors, brain, and spleen) resected.

7.2

Lung Tissue Digestion for Cell Isolation
Lungs bearing 4T1 pulmonary metastases were minced manually and digested with

collagenase (Worthington, Franklin County, OH; 250 U/ml in PBS) and dispase (Roche,
Indianapolis, IN; 2.4U/ml in PBS) for 30 minutes at 37ºC with intermittent shaking. Enzymatic
digestion was neutralized with growth media (DMEM with 2% FBS). The samples were
centrifuged at 300 x g for 8 minutes. The supernatant lysate was discarded, and the cell pellet
resuspended in growth media (DMEM with 5% FBS). The samples were passed through a 70 m
cell strainer (Fisher Scientific), washed once in growth media (DMEM with 2% FBS), and
incubated in Red Blood Cell Lysis buffer (BD Pharmigen, San Jose, CA) for 15 minutes at room
temperature in the dark. After centrifugation at 200 x g for 5 minutes, the supernatant was
carefully aspirated, and the pellet was resuspended in growth media (DMEM with 2mM EDTA
and protease inhibitors; Thermo Fisher Scientific). The samples were transferred into 35 m
strainer-capped flow cytometry tubes for flow cytometric analysis.

7.3

FACS Recovery of Pulmonary Metastatic 4T1-Luc+mCherry+ Tumor Cells
For fluorescence-activated cell sorting (FACS) analysis of the prepared single-cell

suspensions of mouse lung tissue samples, the cells were prepared at a concentration of 1 million
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cells/ mL and pre-gated to exclude non-viable cells, tissue debris and cell clumps. Lung cells
recovered from a healthy tumor-free mouse were used as gating control. 4T1-Luc+ mCherry+
tumor cells from pulmonary metastases were recovered based on gating with mCherry
fluorescence. 50,000 mCherry+ singlets were analyzed per sample with a FACSAria II /FlowJo
software (BD Biosciences, San Jose, CA).

7.4

Recovery of Phage-Displayed Peptides from Metastatic Tumor Cells
The FACS sorted 4T1-Luc+ mCherry+ tumor cells recovered from pulmonary

metastases were resuspended in growth media (DMEM with 10% FBS). The cell suspension was
homogenized in 1mL glass douncers (Sigma Aldrich, St. Louis, MO) to rupture the cells and
extravasate the internalized phage-displayed peptides. Following centrifugation at 14,000 rpm,
the bound phage was eluted, and used to infect K91 E. coli host cells. Bacteriophage was isolated
from K91 E. coli by polyethylene glycol (PEG) precipitation, amplified, purified, and
resuspended in PBS as described previously (179). Through K91 E. coli infection, bacteriophage
enumeration was performed using the double-layer agar technique in LB agar plates (20g/L LB
Agar, 0.01g/L Tetracycline and 0.05g/L Kanamycin; Thermo Fisher Scientific).

7.5

Enrichment of Peptides in Rounds 2 and 3 of In Vivo Bio-panning
1010 TU of phage recovered from Round 1 of selection was used as input phage for the

next round of in vivo selection and were recovered after 3 hours of circulation as described from
Sections 7.1 to 7.4. Between each round, the foreign DNA inserts and encoded peptide sequences
were determined for the top 10 most enriched phage clones to gauge the selection process and the
absence of contamination, as described in Section 7.6. These phage-displayed peptide clones were
bulk-amplified and subsequently pooled as described for the next round of in vivo selection (179).
A total of three rounds of selection was performed.
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7.6

PCR, DNA Sequencing and Insert Analysis
Following the final round of in vivo selection, the eluted phages were used to infect

K91 E. coli host cells. The bacteriophage-infected K91 host cells were serially diluted in LB Broth
(25g/L LB Broth, 0.01g/L Tetracycline, and 0.05g/L Kanamycin; Thermo Fisher Scientific).
1000-fold dilutions were plated using the double-layer agar technique in LB agar plates and
incubated for 12 hours at 37 ºC to form plaques. Individual clones were isolated using sterile
toothpicks and stored in 50% glycerol (Fisher Scientific) stocks in a 96 well format for future
amplification. The insert size of each phage clone was analyzed by PCR. Insertless Fd-Tet and DWAT phages were used as negative and positive controls. The PCR reactions were carried out in
a 10 L reaction volume containing a single colony of phage infected K91 E. coli, 5 L Azura 2X
Taq Mix (Azura Genomics Inc., Raynham, MA), 2 L of the forward primer 5 TTAACTCCCTGCAAGCCTCA-3

and

2 L

of

the

reverse

primer

5 -CCCTCATAGTTAGCGTAAGC-3 and 1 L PCR grade water (Thermo Fisher Scientific).
The PCR reactions were performed using a Mastercycler Pro Thermal Cycler (Eppendorf,
Hauppauge, MA) at the following conditions: 25 cycles of denaturation at 94ºC for 10 seconds;
annealing at 60ºC for 30 seconds; and extension at 72ºC for 60 seconds. The product size was
assessed by 1.8% agarose gel electrophoresis in 1X TAE buffer (Tris-Acetate EDTA Buffer) at
80 volts for 40 minutes. PCR product clean up and DNA sequencing to ascertain the displayed
foreign peptide of each phage was carried out by Epoch Life Sciences (Houston, TX). Sanger
sequencing

was

done

using

the

M13-pIII

sequencing

primer

5 -TTAACTCCCTGCAAGCCTCA-3 . The automated Sanger sequences were represented as
chromatograms, analyzed using the Chromas software (Technelysium Pty Ltd, Queensland,
Australia). The amino acid sequences of the fused peptide inserts were deduced from the DNA
sequence using the ExPASy Bioinformatics Resource Portal (SIB, University of Lausanne,
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Switzerland). Multiple sequence alignment of the selected phage-displayed BLMP clones from
each round was performed using Clustal (Omega) software (EMBL-EBI, Cambridgeshire, UK).
The sequences were then analyzed by the BLAST algorithm (NLM, Bethesda, MD) for homology
with known or putative cancer correlations, identify the presence of consensus motifs, and to
define clones for further analyses.

8. In Vitro Phage-Displayed Peptide Homing Validation
8.1 Phage-Displayed Peptide Internalization Assay
The relative specificity of phage-displayed BLMP clones was assessed individually in
vitro. Cells were grown to 60% confluency in a 24-well tissue culture plate (Costar, Fisher
Scientific) overnight at 37ºC in growth medium (DMEM with 10% FBS). The growth media
was removed and a new medium (DMEM with 2% FBS) with either 10 9 TU of BLMP clones or
insertless phage separately and incubated at 37ºC for 5 hours. Insertless Fd-Tet phage was used
as a negative control. The adherent cells were washed thrice with 1X PBS solution, detached with
0.25% trypsin-EDTA, and resuspended in 2mL growth media (DMEM with 10% FBS). Cell count
for each sample was determined individually using a hemocytometer. The internalized BLMP
clones were recovered by rupturing the cell membranes using glass douncers. The individual
phage-displayed BLMP clone samples were centrifuged at 14,000rpm for 5 minutes. The cell
lysate of each sample containing the extravasated BLMP clones was used to infect K91 E. coli.
The bacteriophage infected K91 host cells were serially diluted in LB Broth. 1000-fold dilutions
were plated using the double-layer agar technique in LB agar plates and incubated for 12 hours at
37ºC to form plaques. The homing specificity of each BLMP clone was quantified as a ratio of
TU recovered to the total number of cells.
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8.2 Phage-Displayed Peptide Internalization Validation by Immunofluorescence
Cells were grown to 60% confluency in a 24-well tissue culture plate (Costar, Fisher
Scientific) overnight at 37ºC in growth medium (DMEM with 10% FBS). The growth media
was removed and 0.2L new medium (DMEM with 2% FBS) with either 109 TU of BLMP clones
or insertless phage separately and incubated at 37ºC for 5 hours. Insertless Fd-Tet phage was used
as a negative control. The adherent cells were washed thrice with 1X PBS solution to remove nonspecific unbound phage. The cells and bound phage were fixed by the addition of 4%
formaldehyde in PBS solution and blocked with a Serum-free protein block (Pierce, Thermo
Fisher Scientific) for 1 hour at room temperature. The internalization of phage by the cells was
probed by the addition of a rabbit polyclonal anti-Fd bacteriophage primary antibody (Sigma
Aldrich; 1:500) incubated at 4 °C for 12 hours. The wells were extensively washed with TBS
(PBS/0.05% Tween-20, Thermo Fisher Scientific) three times before being incubated with
donkey anti-rabbit Cy3-conjugated (Jackson ImmunoResearch Laboratories. INC, West Grove,
PA; 1:300) Secondary IgG for one hour in the dark at room temperature. Nuclei were stained with
Hoechst 33258 (Invitrogen, Grand Island, NY). Fluorescence images were acquired with a Nikon
Eclipse TE2000E Widefield Fluorescence Microscope (Nikon Instruments Inc, Melville, NY).

9. In Vivo Phage-Displayed Peptide Homing Validation
Individual phage-displayed BLMP clones were injected into vehicle and cisplatintreated (2.5mg/kg) treated spontaneous and experimental metastasis murine models. The BLMP
clones were allowed to circulate for three hours, after which the mice were anesthetized using
tribromoethanol (150mg/kg) administered through intraperitoneal injections. Lung perfusion,
organ resection, and subsequent fixation were performed as described in Sections 2, 3, and 5. The
tissues harvested from the mice were embedded in paraffin. Slides with sections of formalin-fixed
tissues and tumors embedded in paraffin were deparaffinized and rehydrated as described (180).
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Antigen retrieval was performed by heating the slides in 10mM sodium citrate buffer (Pierce,
Thermo Fisher Scientific) at 95°C for 20 minutes and slowly cooled to room temperature for
another 20 minutes. The tissue sections were blocked with a Serum-free protein block solution
and incubated at room temperature for 2 hours. Primary antibodies (4°C, 12 16 hours) and
secondary antibodies (RT, 1 hour) were applied in TBS. The following primary antibodies were
used: rabbit anti-Fd (Sigma-Aldrich; 1:500), goat anti-mouse CD31 (Santa Cruz Biotechnology,
Santa Cruz, CA, 1:150), mouse anti-E Cadherin (BD Biosciences, San Jose, CA; 1:100), mouse
anti-N Cadherin (BD Biosciences, San Jose, CA; 1:100) and mouse anti-Cytokeratin
(MyBioSource, San Diego CA; 1:200). Secondary IgG used were as follows: donkey anti-mouse
Alexa 488-conjugated (Invitrogen, 1:300) and donkey anti-rabbit Cy3-conjugated (Jackson
ImmunoResearch Laboratories. INC; 1:300). Nuclei were stained with Hoechst 33258.
Fluorescence images were acquired with a Nikon Eclipse TE2000E Widefield Fluorescence
Microscope (Nikon Instruments Inc). Hematoxylin and eosin (H&E) staining was performed by
histology CORE (IMM-UTH, Houston, TX). Images of H&E stained tissue sections were
obtained with Zeiss Axio Scope Brightfield Microscope (Carl Zeiss Meditec, Inc., Dublin, CA).

10. Design and Synthesis of Hunter-Killer Peptides
All hunter-killer peptides were made as proteolysis-resistant all D-amino acid
peptides. The apoptotic domain, a cationic amphipathic sequence (KLAKLAK)2, was linked to
the targeting domain via an amino hexanoic acid linker (NH-(CH2)5-CO). Peptides were
synthesized by conventional peptide chemistry, cyclized via cysteines, purified to >90% by
HPLC, and quality controlled (mass spectroscopy). Peptide instability and proteolytic cleavage in
vivo were addressed via L-amino acid to D-amino acid sequence conversion accompanied by
terminal N or C- terminus blockade. Lyophilized peptide acetate salt powder was reconstituted in
PBS solution to a concentration of 10 mmol/L, and aliquots were stored at -20ºC until dilution in
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PBS, filtration, and use. The following hunter-killer peptides were designed and purchased from
Celtek Bioscience (Franklin, TN):
1. HK-BLMP7: Composed of breast lung metastasis (BLM) homing peptide BLMP7 (sequence:
CLRHSSKIC) conjugated to apoptotic (KLAKLAK)2 domain.
2. HK-BLMP8: Composed of BLM-homing peptide BLMP8 (sequence: CRAGVGRGC)
conjugated to apoptotic (KLAKLAK)2 domain.
The following peptides were designed and purchased from Ambiopharm (North Augusta, SC):
1. D-CAN: Composed of Adipose stromal cell (ASC) homing peptide WAT7 (sequence:
CSWKYWFGEC) conjugated to apoptotic (KLAKLAK)2 domain.
2. (KLAKLAK)2:

Composed

of

uncoupled

lytic

amphipathic

sequence

(KLAKLAKKLAKLAK).

11. Biotin-labeled HK-BLMP Internalization Assay In Vitro
HK-BLMP7 and HK-BLMP8 peptides were labeled with biotin using the Sulfo-NHSLC-Biotin Kit (APExBIO, Houston, TX) according to the manufacturer s guidelines. Cells were
cultured as specified above and incubated with biotin-labeled HK-BLMP7 (30 moles/L) or HKBLMP8 (20 moles/L) peptides for 5 hours at 37ºC. The adherent cells were fixed and blocked,
as described in Section 8.2. The internalization of the biotin-labeled peptide by the cells was
probed by the addition of Streptavidin-Cy3 (Zymed, Thermo Fisher Scientific; 1:50) for one hour
in the dark at room temperature. Nuclei were stained, and fluorescence images were acquired as
described in Section 8.2.
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12. In Vitro Assay for Cell Viability
Cells were grown to 60% confluency in 48-well tissue culture plates (Costar, Fisher
Scientific) overnight at 37ºC in growth medium (DMEM with 10% FBS). HK-BLMP7, HKBLMP8, D-CAN, or uncoupled (KLAKLAK)2 was added to each well. Peptide concentrations
ranging from 1 to 300 moles/L were added to 0.2 mL serum-free media in each of the wells and
incubated for at 37ºC for 8 -24 hours. Trypan blue exclusion assay and the cleaved-caspase3 assay
was used to determine cell viability in peptide-treated cell lines.

12.1 Validation of Cell Viability by Trypan-Blue Staining
Following hunter-killer peptide treatment, live and dead cells were distinguished by
staining with 0.4% Trypan Blue solution (MP Biomedicals, Santa Ana, CA) for 10 minutes. The
solution was slowly decanted and replaced with 4% formaldehyde in PBS solution to fix the cells.
The cells were imaged and analyzed with a Nikon Eclipse TE2000E Widefield Fluorescence
Microscope (Nikon Instruments Inc.).

12.2 Validation of Apoptosis induction by Cleaved-Caspase 3 Staining
Following hunter-killer peptide treatment, cells were fixed and blocked, as described
in Section 8.2. Cell viability was probed by the addition of primary antibody: anti-Asp175-cleaved
Caspase3 (Cell Signaling Technology, Beverly, MA; 1:100) incubated at 4 °C for 12 hours.
Secondary donkey anti-rabbit Cy3-conjugated (Jackson ImmunoResearch Laboratories. INC;
1:300) (Invitrogen; 1:150) for one hour in the dark at room temperature. Nuclei were stained, and
fluorescence images were acquired as described in Section 8.2.
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13. In Vivo Metastasis Ablation Study with HK-BLMP8
Female Balb/c mice (stock 000651, Jackson) were ten weeks old at the start of the
experiment. The mice were implanted with 4T1 breast tumors, as described in Section 3.3. Once
the tumors were palpable, the mice were split into two cohorts (n=5). Mice in each cohort were
administered twelve doses of either vehicle (1X PBS) or HK-BLMP8 peptide (10mg/kg)
subcutaneously into the lower back over a period of 4 weeks. During this period, the mice were
periodically monitored and subjected to weekly BLI to monitor and image metastatic progression.
Upon reaching morbidity, the animals were then euthanized.

14. Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 8 software (GraphPad, La
Jolla, California). Multiple row t-tests were used to compare changes in tumor volume between
vehicle control, cisplatin-treated, and hunter-killer peptide treated mice. Two-way Anova was
used to compare the binding efficiency of the six BLMP clones across different cell lines. The
Log-rank (Mantel-Cox) test was used to compare the survival probability between vehicle control
and hunter-killer peptide treated mice. Data were represented as Mean ± SEM.
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Chapter 4: Results
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1. Cisplatin treatment elicits no tumor response but exacerbates metastatic burden
In order to conduct the in vivo phage-displayed peptide library screen for
chemoresistant TNBC pulmonary metastases, the 4T1 orthotopic syngeneic murine model was
selected. This in vivo model of spontaneous metastasis has been well characterized and has been
used in several studies for the elucidation of the mechanisms implicated in chemoresistance
evolution and subsequent metastatic progression (181-184). Dual-luciferase and mCherry labeled
4T1 adenocarcinoma cells obtained from Dr. Sendurai Mani s lab, were orthotopically implanted
into the mammary fat pad of Balb/c mice. Once the tumors reached a volume of 200mm3, the
mice were randomized into two groups (n=20/cohort) and treated with vehicle control or 2.5mg/kg
cisplatin retro-orbitally for three weeks. The tumor volumes were measured thrice a week until
the mice attained morbidity. Further, metastatic progression was measured weekly using noninvasive bioluminescence imaging until the mice succumbed to metastasis-induced mortality.
Based on Welch s t-test analysis, no significant difference (p=0.5735) in tumor
volumes was observed between the two groups during the treatment period (Figure. 1A). These
observations were sustained even upon treatment completion (Figure. 1A). These results suggest
that cisplatin administration had no effect on primary tumor growth. However, upon analysis of
non-invasive bioluminescence images of the mice, a significant difference in metastatic burden
was indicated between the groups (Figure. 1B). In the cisplatin-treated mouse cohort, cancer
progression and subsequent pulmonary metastatic burden were significantly higher when
compared to the vehicle-treated mouse cohort (Figure. 1B). These observations were further
corroborated through pulmonary metastases nodule quantification. At the experimental endpoint,
mice were euthanized, and their lungs subjected to PBS perfusion. The lungs were then fixed in
formalin until the metastatic nodules were bleached to amelanotic gray/white nodules
(Figure. 1C). This was followed by a blind enumeration of metastatic lung nodules of both mice
cohorts. The cisplatin-treated mice demonstrated a significantly higher (p
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0.01) pulmonary

metastatic nodule burden when compared to the vehicle control group (Figure. 1D). Together,
these data suggest that cisplatin administration elicits no primary tumor response but does
exacerbate cancer progression and metastatic burden (Figure. 1).
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Figure. 4: Cisplatin treatment elicits no tumor response but exacerbates metastatic burden
A. Primary Tumor growth curves for vehicle versus cisplatin treated cohorts (n = 20/cohort).
Vehicle and cisplatin (2.5mg/kg) were administered retro-orbitally weekly, for three weeks.
Tumor volumes were calculated using the formula : length x (width)2 x 0.52. Tumor volumes
are shown as mean ± SEM.
B. Non-invasive bioluminescence imaging to monitor metastatic progression. The luciferase
signal and luminescence were assessed in vehicle and cisplatin-treated cohorts respectively.
C. Quantification of metastatic nodules of vehicle and cisplatin treated mice cohorts (n = 5
/cohort) at experimental endpoint (**, p 0.01). Metastatic nodule number shown as mean ±
SEM.
D. Representative images of primary tumors and lung metastases in vehicle and cisplatin-treated
cohorts.
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2. A screen for phage-displayed breast lung metastasis homing peptides
In order to isolate peptides specifically homing to chemoresistant breast lung
metastases (BLM), the in vivo phage display methodology was adopted to investigate the
interactions between phage-peptides mimicking the ligands of novel receptors expressed
preferentially on the tissues or organs of interest (140, 142, 185). In vivo phage display screening
was performed in the 4T1 chemoresistant spontaneous TNBC metastasis model described above
(Figure. 4). This model was chosen because it supports the basis of our hypothesis that upon
chemoresistance evolution, mammary tumor cells acquire an aggressive phenotype that promotes
metastatic progression and malignancy-associated morbidity (181, 182).
In vivo phage display bio-panning was combined with the isolation of metastatic tumor
cells by fluorescence-activated cell sorting (FACS) from BLM cell suspensions. We focused on
the isolation of phage-peptides that specifically bound to the mCherry positive cell sub-population
of BLM from the lung (Figure. 5A). Prior to in vivo phage-peptide bio-panning, insertless Fd-Tet
phage was intravenously injected into the mouse model for non-specific phage-peptide binding
normalization. Three rounds of in vivo bio-panning were performed. At the start of the first round,
a mixture of cyclic CX7C and CX8C (C: disulfide-bonded cysteines; X: any amino acid) random
phage-peptide libraries were injected into the chemoresistant 4T1 spontaneous metastasis model.
This approach enabled the selection of pulmonary TNBC metastasis homing phage-peptide
probes from a pool of over 1010 combinatorial peptides displayed as a fusion on the pIII protein
of filamentous M13 bacteriophage.
For every round, the output of the previous round was quantified, amplified, pooled,
and used as the input of the subsequent rounds. Following each round of bio-panning, the phagepeptides recovered from the FACS-sorted mCherry positive and mCherry negative cell subpopulations were individually tittered using K91 E.coli bacterial host cells (Figure. 5B). Only
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those E.coli cells infected with phage formed plaques on double-layered tetracycline rich LB agar
plates (Figure. 5B). After titration, the phage binding efficiency was calculated by dividing the
phage TU by the number of FACS sorted cells. The relative specificity of phage-displayed
peptides binding to mCherry positive tumor cell populations was compared to that of the mCherry
negative host cell population. In Rounds 2 and 3, a significant enrichment (p

0.001) in the

number of phage-peptides homing to mCherry positive metastatic cell populations was observed
(Figure. 5C).
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Figure. 5: An in vivo phage-displayed peptide library screen for peptides homing to cisplatin
resistant metastatic tumor cells
A. FACS analysis of mouse lung tissue samples. Tumor cells from pulmonary metastases were
recovered based on mCherry fluorescence gating. Pulmonary cells recovered from healthy
tumor-free mice used as gating control.
B. Comparison of phage infected E.coli plaque density between mCherry positive tumor cells
from pulmonary metastases and mCherry negative host lung cells over three rounds of in vivo
phage-displayed peptide library bio-panning. Fd-Tet: Insertless control phage used for
normalization.
C. Phage-displayed peptides bound to metastatic mCherry positive tumor cells, in parallel with
phage-displayed peptides bound to host lung cells, were quantified, amplified, pooled, and
used for subsequent rounds of bio-panning. Increased recovery of phage transforming units
(TU) in successive rounds reflects the enrichment of phage-displayed peptides homing to the
metastatic mCherry positive tumor cells. Shown are mean ± SEM for duplicate measurements.
Two-way ANOVA indicates statistically significant differences within mCherry positive and
mCherr negative groups assessed b Sidak s multiple comparisons test and is denoted as:
***,p

0.001 and ns: non-significant (p > 0.05).
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3. Nine novel breast lung metastasis homing phage-peptides were identified through in vivo
screening of chemoresistant TNBC pulmonary metastases
After three rounds of synchronous in vivo bio-panning, nine CX7C phage-peptide
clones were repeatedly recovered from chemoresistant mCherry positive metastatic tumor cells
with a frequency above 1%. These phage-displayed peptides were termed breast lung metastasis
peptides (BLMP), BLMP0 through BLMP8 (Figure. 6A). The homing specificity of each clone
was assessed by quantifying the frequency of phage coding for each peptide. Each BLMP clone
demonstrated a significant enrichment (p

0.001) between Rounds 2 and 3 of in vivo phage bio-

panning (Figure. 6A). BLMP7 stood out owing to its marked capacity to home to chemoresistant
BLM. BLMP7 represented 59.21% of the recovered clones in Round 3. BLMP5, BLMP0, and
BLMP4 were the next most enriched BLMP clones with a frequency of 8.69%, 6.67%, and 6.58%,
respectively (Figure. 6A). Although BLMP1, BLMP2, and BLMP3 had relatively high homing
frequency in Round 2, they were absent in Round 3 (Figure. 6A). Thus, these three BLMP clones
were excluded from further analysis.
BLMP0, BLMP4, BLMP5, BLMP6, BLMP7, and BLMP8 were individually amplified
in K91 E.coli. PCR was performed on the bacteriophage infected E.coli to amplify the fragment
containing BLMP inserts. The products were analyzed by agarose gel electrophoresis. All BLMP
clones had a 34 bp-sized insert, unlike insertless Fd-Tet phage (Figure. 6B). Individual BLMP
clones were then characterized by DNA sequencing. The amino acid sequences of the BLMPs
were computed from their cognate DNA sequences using the ExPASy bioinformatics portal. The
amino acid sequences and the overall charge of each BLMP clone were summarized (Figure. 6C).
The net charge of each clone was calculated as the total of the charge of each amino acid present
in the BLMP sequence. The insert CLRHSSKIC constituted over 60% of the clones identified by
the screen (Figure. 6C).
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Figure. 6: Summary of top BLMP clones enriched over three rounds of in vivo phagedisplayed peptide library bio-panning
A. Assessment of individual BLMP clone frequencies over Round 2 and Round 3 of in vivo phage
displayed peptide library bio-panning. Shown are mean ± SEM for triplicate measurements.
Two-way ANOVA indicates statistically significant differences within Rounds 2 and 3 by
Sidak s multiple comparisons test and is denoted as: ***, p 0.001 and ****, p

0.0001.

B. Analysis of PCR product size of individual BLMP clones by DNA agarose electrophoresis.
Fd-Tet : Insertless control cphage. D-WAT: positive control phage.
C. Summary of the individual BLMP clone characteristics.
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4. All BLMP clones bind specifically to murine cancer cell lines in vitro
The tropism of BLMP clones for TNBC cell lines was further validated through an in
vitro immunofluorescence assay. This assay was performed using a specific antibody against M13
filamentous phage. Phage particles displaying the selected BLMP inserts were incubated with
murine parental and cisplatin-resistant 4T1.2 adenocarcinoma cells and 3T3L1 murine fibroblasts
overnight. Wild-type insertless Fd-Tet phage was used as negative phage control. The assay
results demonstrated a pronounced red fluorescence signal for all BLMP clones in both 4T1
parental and 4T1 cisplatin-resistant TNBC cell lines. Further, no BLMP clone binding (red) was
observed in murine 3T3L1 fibroblasts. These observations suggest that the BLMP clones, home
specifically to only TNBC cell lines. However, no significant difference in binding capacity was
observed between the 4T1 parental and cisplatin-resistant cell lines (Figure. 7A).
The relative specificity of individual BLMP clones to TNBC cancer cell lines was
further probed through an internalization assay. Phage particles displaying the selected BLMP
inserts were incubated overnight with the cell lines described above. Additionally, murine
melanoma B16F10 cell lines were used to evaluate the possible existence of BLMP clone crossreactivity in different murine cancer models. Upon incubation, the BLMP clones binding to each
cell line were recovered, pooled, and quantified through titration against K91 E.coli bacteria.
BLMP binding efficiency was reported as a ratio of phage TU recovered and cell count (Figure.
7B). Compared to 3T3L1 negative control, all BLMP clones except BLMP5 and BLMP6 showed
significant binding efficiency (p

0.0001) to all murine cancer cell lines. Hence, BLMP5 and

BLMP6 were excluded from further analysis (Figure. 7B). BLMP4 and BLMP7 stood out owing
to the significant difference (p 0.01) in binding capacity between parental and cisplatin-resistant
4T1.2 adenocarcinoma cells. BLMP8 stood out owing to its significantly higher (p
binding efficiency to murine B16F10 cells (Figure. 7B).
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Figure. 7: Validation of phage-displayed BLMP clone specificity to cancer cells in vitro
A. Anti-phage (Cy3) immunofluorescence in parental and cisplatin-resistant murine 4T1.2
adenocarcinoma and 3T3L1 fibroblast cell lines incubated with phage-displayed BLMP
clones overnight. Red (anti-phage) immunofluorescence signal upon digital channel merging
indicates localization of BLMP clones on 4T1 parental and cisplatin-resistant cell lines but
not on 3T3L1 murine fibroblasts. Fd-Tet: Insertless control phage. Nuclear DAPI staining is
blue. Scale bar: 50 m.
B. Assessment of individual phage-displayed BLMP clones homing for parental and cisplatinresistant murine 4T1.2, murine B16F10 melanoma and murine 3T3L1 fibroblast cell lines.
Cells were incubated with phage-displayed BLMP clones overnight. Relative specificity of
phage homing was calculated as a ratio of TU recovered and cell count. Shown are mean ±
SEM for triplicate measurements. Two-way ANOVA indicates statistically significant
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differences assessed b Sidak s multiple comparisons test. *, p
****, p

0.01; ***, p

0.001 and

0.0001 indicates comparison between 3T3L1 negative control and cancer cell lines

for the same peptide. ***, p

0.001 and ****, p

0.0001 indicates comparison between

parental and cisplatin-treated murine 4T1.2 adenocarcinoma cell lines for the same peptide.
ns: non-significant (p > 0.05).
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5. Both BLMP7 and BLMP8 demonstrate pulmonary metastases-specific tropism in a
spontaneous TNBC metastasis model
The tropism of BLMP clones to pulmonary metastases was explored in the 4T1
adenocarcinoma spontaneous metastasis model. Phage particles bearing the BLMP inserts were
intravenously injected into vehicle and cisplatin-treated mice (n = 5/cohort). Following the
systemic circulation of phage for 3 hours, the mice were euthanized. Their organs (lung, primary
tumor, kidney, pancreas, liver, and brain) were resected and subsequently formalin-fixed for
future analysis. Immunofluorescence assay was performed in formalin-fixed paraffin-embedded
organ sections of mice from both vehicle and cisplatin-treated cohorts. The assay was performed
using a specific antibody against M13 filamentous phage.
In the vehicle-treated 4T1 mouse model, BLMP7 with CLRHSSKIC motif
demonstrated localization (red) to the indicated areas of pulmonary metastases and liver. In
contrast, the primary tumor and other control organs (pancreas, kidney, and brain) showed no
BLMP7 (red) localization (Figure. 8A). Similar results were observed in the cisplatin-treated 4T1
mouse model, with additional non-specific BLMP7 (red) trapping in the kidneys and livers of
cisplatin-treated mice (Figure. 8B). These results suggest that BLMP7 homes specifically to only
TNBC pulmonary metastases regardless of chemotherapy administration.
Interestingly, in addition to pulmonary metastases homing, BLMP8 with
CRAGVGRGC motif, demonstrated localization (red) in the primary tumor as well. However,
BLMP8 did not localize to other control organs (pancreas and brain). These observations were
noticed in both vehicle (Figure. 8C) and cisplatin-treated (Figure. 8D) 4T1 mouse models. In the
cisplatin-treated cohort, additional non-specific BLMP8 (red) trapping in the kidneys and liver
were noted (Figure. 8D). These results suggest that BLMP8 homes not only to the spontaneous
pulmonary metastases but also to the original localized TNBC primary tumors. As observed for
BLMP7, BLMP8 homing was independent of chemotherapy administration.
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Upon closer analysis of BLMP7 and BLMP8 homing in the indicated areas of
pulmonary metastases, it was noted that the phage-displayed peptides (red) consistently localized
along the invasive edges of the macro-metastases (Figures. 8 A-D). Distribution of the phage to
tumor cells with metastases was further probed through immunofluorescence assay with an
antibody against Cytokeratin 14 (Basal TNBC marker). In the 4T1 spontaneous metastasis model,
no co-localization of phage with Cytokeratin 14 was observed (data not shown).
The pulmonary metastases-specific tropism demonstrated by both BLMP7 and BLMP8
clones was further corroborated in healthy metastasis-free mice. C57BL/6 mice (n=4) were
intravenously injected with either BLMP 7 or BLMP8. The organs of the mice were processed as
described above. Neither BLMP7 nor BLMP8 homed to lung tissue or control organs (pancreas,
kidney, and brain) of healthy mice (Figures. 9A and 9B).
BLMP0 and BLMP4 clones were also administered intravenously into vehicle and
cisplatin-treated mice. Contrary to in vitro BLMP clone homing data discussed above (Figure. 7),
neither BLMP0 nor BLMP4 homed to TNBC pulmonary metastases or primary tumors (data not
shown). Thus, both BLMP0 and BLMP4 were excluded from future analysis.
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Figure. 8: BLMP7 and BLMP8 home to pulmonary metastases in the 4T1 TNBC mouse
model
A. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
vehicle-treated mice intravenously injected with BLMP7. Red (anti-phage) signal upon digital
channel merging indicates localization of BLMP7 in the indicated areas of pulmonary
metastases (b), and liver (e), but not in primary tumor (d), kidney (f), pancreas (g), and
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m.
B. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
cisplatin-treated mice intravenously injected with BLMP7. Red (anti-phage) signal upon
digital channel merging indicates localization of BLMP7 in the indicated areas of pulmonary
metastases (b), liver (e), and kidney (f), but not in primary tumor (d), pancreas (g), and
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m.
C. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
vehicle-treated mice intravenously injected with BLMP8. Red (anti-phage) signal upon digital
channel merging indicates localization of BLMP8 in the indicated areas of pulmonary
metastases (b), primary tumor (d), and liver (e), but not in kidney (f), pancreas (g), and
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m.
D. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
cisplatin-treated mice intravenously injected with BLMP8. Red (anti-phage) upon digital
channel merging indicates localization of BLMP8 in the indicated areas of pulmonary
metastases (b), liver (e), and kidney (f), and primary tumor (d), but not in pancreas (g), and
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m.
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Figure. 9: Absence of BLMP7 and BLMP8 homing in metastases-free mice. Anti-phage (Cy3)
immunofluorescence in serial paraffin sections of formalin-fixed organs of tumor-free mice
intravenously injected with phage-displayed BLMP7 (Figure. 9A) or BLMP8 clones (Figure. 9B).
Red (anti-phage) immunofluorescence signal upon digital channel merging indicates localization
of phage observed for both BLMP7 (Figure. 9A) and BLMP8 (Figure. 9B) in liver (c), but not in
the lungs (b), kidney (d), pancreas (e), and brain (f). Nuclear DAPI staining is blue. Scale bar:
100 m.
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6. Only BLMP8 demonstrates pulmonary metastases-specific tropism in an experimental
melanoma metastasis model
Since neither BLMP7 nor BLMP8 demonstrated chemoresistance specific pulmonary
metastasis homing, we hypothesized that both BLMP7 and BLMP8 clones might home to
pulmonary metastases in other cancer sub-type settings. To test this hypothesis, the B16F10
melanoma mouse model was selected for further analysis. This mouse model was chosen as
BLMP8 demonstrated a significantly high binding efficiency to murine B16F10 melanoma cells
in vitro (Figure. 7B). Further, the B16F10 melanoma model is a well-characterized model of
experimental metastasis (186, 187). Phage particles bearing the BLMP inserts were intravenously
injected into vehicle and cisplatin-treated B16F10 mouse models (n=3/cohort). Phage circulation,
organ recovery, and immunofluorescence analysis of formalin-fixed paraffin-embedded organ
sections was performed as described previously.
In both vehicle and cisplatin-treated B16F10 mouse model, BLMP7 demonstrated no
localization (red) to either pulmonary metastases or control organs (Figures. 10A and 10B). These
results suggest that BLMP7 homes to pulmonary metastases only in TNBC mouse models.
Interestingly, BLMP8 (red) demonstrated localization in pulmonary metastases but not to the
control organs of both vehicle and cisplatin-treated B16F10 mouse models (Figures. 10C and
10D). Like the 4T1 cisplatin-treated cohort, non-specific BLMP8 (red) trapping in the liver and
kidneys of B16F10 cisplatin-treated mice was also noted (Figure. 10D). These results suggest that
BLMP8 homes to pulmonary metastases irrespective of the cancer sub-type setting, thus
corroborating the translation potential of BLMP8. Further, BLMP8 homing was independent of
chemotherapy administration. Similar to the 4T1 spontaneous metastasis model, BLMP8 (red)
localization within B16F10 pulmonary metastases was observed along the invasive edges of the
macro-metastases (Figures. 10C and 10D).
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Figure 10: BLMP8 homes to pulmonary metastases in the B16F10 melanoma mouse model
A. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
vehicle-treated

mice

intravenously

injected

with

BLMP7.

Red

(anti-phage)

immunofluorescence signal upon digital channel merging indicates localization of BLMP7 in
liver (c), but not in the indicated areas of pulmonary metastases (b), kidney (d), pancreas (e),
and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m.
B. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
cisplatin-treated

mice

intravenously

injected

with

BLMP7.

Red

(anti-phage)

immunofluorescence signal upon digital channel merging indicates localization of BLMP7 in
liver (c), and kidney (d), but not in the indicated areas of pulmonary metastases (b), pancreas
(e), and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m.
C. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
vehicle-treated

mice

intravenously

injected

with

BLMP8.

Red

(anti-phage)

immunofluorescence signal upon digital channel merging indicates localization of BLMP8
in liver (c), but not in the indicated areas of pulmonary metastases (b), kidney (d), pancreas
(e), and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m.
D. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of
cisplatin-treated

mice

intravenously

injected

with

BLMP8.

Red

(anti-phage)

immunofluorescence signal upon digital channel merging indicates localization of BLMP8 in
liver (c), and kidney (d), but not in the indicated areas of pulmonary metastases (b), pancreas
(e), and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m.
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7. BLMP7 and BLMP8 home to mesenchymal tumor cells in lung metastases
Phage-displayed BLMP localization was restricted to the invasive edges of metastases.
This prompted us to explore the favorable tumor cell features that attracted phage-displayed
peptide binding. Thus, the co-localization of BLMP7 and BLMP8 with markers of EMT, Ecadherin, and N-cadherin, was investigated. In the 4T1 spontaneous metastasis mouse model,
BLMP7 and BLMP8 localization (red) was absent in pulmonary metastases cells positive for
epithelial E-cadherin (Figure. 11 A-C). Further, a similar trend was observed in the primary
tumors obtained from mice injected with phage-displayed BLMP8 (Figure. 11B and 11C). In the
B16F0 experimental metastasis mouse model, BLMP8 (red) also demonstrated a localization
pattern similar to 4T1 spontaneous pulmonary metastases (Figure. 11D). In this model, only
BLMP8 co-localization was probed due to a lack of BLMP7 homing to B16F10 pulmonary
metastases. These observations remained consistent across the vehicle and cisplatin-treated
models.
However, in the 4T1 spontaneous metastasis mouse model, both BLMP7 and BLMP8
co-localized (yellow) with N-cadherin positive pulmonary metastatic tumor cells (Figure. 12 AC). Further, a similar trend was observed in the primary tumors obtained from mice injected with
phage-displayed BLMP8 (Figure. 12B and 12C). In the B16F0 experimental metastasis mouse
model, BLMP8 also demonstrated a localization pattern similar to 4T1 spontaneous pulmonary
metastases (Figure. 12D). In this model, only BLMP8 co-localization was probed due to a lack of
BLMP7 homing to B16F10 pulmonary metastases. These observations remained consistent across
vehicle and cisplatin-treated models. Taken together, these data suggest that phage-displayed
BLMP7 and BLMP8 home to mesenchymal tumor cells in primary tumors and pulmonary
metastases.
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Figure 11: BLMP7 and BLMP8 do not home to E-cadherin positive tumor cells
A. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated 4T1 mouse
models, intravenously injected with BLMP7. Upon digital channel merging, the absence of
red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that
BLMP7 doesn t home to E-cadherin positive tumor cells in both vehicle (b) and cisplatintreated (d) pulmonary metastases. Nuclear DAPI staining is blue. Scale bar: 100 m.
B. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases and primary tumors of vehicle-treated 4T1
mouse model, intravenously injected with BLMP8. Upon digital channel merging, the absence
of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that
BLMP8 doesn t home to E-cadherin positive tumor cells in vehicle-treated pulmonary
metastases (b) and primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m.
C. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases and primary tumors of cisplatin-treated 4T1
mouse model, intravenously injected with BLMP8. Upon digital channel merging, the absence
of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that
BLMP8 doesn t home to E-cadherin positive tumor cells in cisplatin-treated pulmonary
metastases (b) and primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m.
D. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated B16F10
mouse models, intravenously injected with BLMP8. Upon digital channel merging, the
absence of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization
indicates that BLMP7 doesn t home to E-cadherin positive tumor cells in both vehicle (b) and
cisplatin-treated (d) pulmonary metastases. Nuclear DAPI staining is blue. Scale bar: 100 m.
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Figure 12: BLMP7 and BLMP8 home to N-cadherin positive tumor cells
A. Anti-phage (Cy3) and anti N-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases of cisplatin and vehicle-treated 4T1 mouse
models, intravenously injected with BLMP7. The co-localization of red (anti-phage) and
green (N-Cadherin) signals upon digital channel merging indicates that BLMP7 does home to
N-cadherin positive tumor cells in cisplatin (b) and vehicle-treated (d) pulmonary metastases.
Nuclear DAPI staining is blue. Scale bar: 100 m.
B. Anti-phage (Cy3) and anti N-cadherin (Alexas-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases and primary tumors of vehicle-treated 4T1
mouse model, intravenously injected with BLMP8. The co-localization of red (anti-phage)
and green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does
home to N-cadherin positive tumor cells in vehicle-treated pulmonary metastases (b) and
primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m.
C. Anti-phage (Cy3) and anti N-cadherin (Alexas-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases and primary tumors of cisplatin-treated 4T1
mouse model, intravenously injected with BLMP8. The co-localization of red (anti-phage)
and green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does
home to N-cadherin positive tumor cells in cisplatin-treated pulmonary metastases (b) and
primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m.
D. Anti-phage (Cy3) and anti N-cadherin (Alexa-488) immunofluorescence in serial paraffin
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated 4T1 mouse
models, intravenously injected with BLMP8. The co-localization of red (anti-phage) and
green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does home to
N-cadherin positive tumor cells in vehicle (b) and cisplatin-treated (d) pulmonary metastases.
Nuclear DAPI staining is blue. Scale bar: 100 m.
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8. Phage-displayed BLMP7 and BLMP8 do not home to epithelial tumor cells in vitro
In order to corroborate that BLMP7 and BLMP8 do home to mesenchymal tumor cells,
we investigated the BLMP homing pattern in vitro with an immunofluorescence assay, using a
specific antibody against epithelial marker E-cadherin. Phage-displayed BLMP7 and BLMP8
were incubated with murine parental and cisplatin-resistant 4T1.2 adenocarcinoma cells, murine
B16F10 melanoma and human MDA-MB-231 adenocarcinoma cells overnight.
All cell lines, including B16F10 and MDA-MB-231 cells, demonstrated BLMP7 (red)
and BLMP8 (red) binding (Figures. 13 A-H). Further, it was observed that 4T1 cells with
pronounced E-cadherin (green) expression demonstrated less BLMP7 and BLMP8 binding (green
arrow). Instead, both BLMP7 and BLMP8 (white arrow) were seen to bind better to cancer cells
with very little to no E-cadherin expression (Figures. 13 A-H). Loss in the E-cadherin expression
is a characteristic feature of cells undergoing EMT, to acquire a more mesenchymal phenotype.
Since phage-displayed peptide homing in seen in tumor cells exhibiting predominantly
mesenchymal characteristics, these data suggest that phage-displayed BLMP7 and BLMP8 home
to cells that have undergone the EMT.
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Figure 13: BLMP7 and BLMP8 home to tumor cells expressing reduced levels of Ecadherin Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in murine
parental and cisplatin-resistant 4T1.2 adenocarcinoma, human MDA-MB-231 adenocarcinoma
and murine B16F10 melanoma cell lines. Cells were incubated with phage-displayed BLMP7 and
BLMP8 clones overnight. Upon digital channel merging, cancer cells exhibiting high level of
green (E-cadherin) signal (green arrow), demonstrate lesser homing of BLMP7 (Cy3) and BLMP8
(Cy3) clones. However, cancer cells exhibiting little to no green signal (white arrow), demonstrate
more specific homing of phage-displayed BLMP7 (Cy3) and BLMP8 (Cy3) clones. Nuclear
DAPI staining is blue. Scale bar: 50 m.
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9. Biotin-labeled HK-BLMP7 and HK-BLMP8 bind specifically to cancer cell lines in vitro
In order to explore the binding specificity of BLMP7 and BLMP8 outside the phage
context, hunter-killer peptide versions of BLMP7 and BLMP8, termed HK-BLMP7 and HKBLMP8, were chemically synthesized. HK-BLMP7 consists of homing motif CLRHSSKIC
conjugated with the KLAKLAKKLAKLAK sequence, with an amino-hexanoic acid linker. HKBLMP8 was designed in a similar manner, with a homing motif of CRAGVGRGC instead. The
amphipathic peptide (KLAKLAK)2 sequence, disrupts cellular mitochondrial membranes through
receptor-mediated cell internalization, to promote programmed cell death (188).
The tropism of HK-BLMP7 and HK-BLMP8 for cancer cell lines was probed through
biotin labeling. The pro-apoptotic potential of HK-BLMP7 and HK-BLMP8 was neutralized
through the binding of biotin molecules to (KLAKLAK)2 s l sine residues. Biotin-labeled HKBLMP7 (B-BLMP7) and biotin-labeled HK-BLMP8 (B-BLMP8) were incubated with murine
parental and cisplatin-resistant 4T1.2 adenocarcinoma cells, murine B16F10 melanoma, human
MDA-MB-231 adenocarcinoma, and 3T3L1 murine fibroblasts for six hours. This was followed
by an in vitro immunofluorescence assay using a Cy3-conjugated streptavidin binding to biotin
on the labeled peptides. Human MDA-MB-231 adenocarcinoma cells were used to study the
translational potential of the hunter-killer peptides. 3T3L1 fibroblasts were used as a negative
control. The results of the assay demonstrated a pronounced red (Cy3) fluorescence signal for
both B-BLMP7 (Figures. 14 A-D) and B-BLMP8 (Figures. 14 F-I) in all cancer cell lines.
However, no signal that could result from peptide binding was observed in murine 3T3L1
fibroblasts (Figures. 14E and 14J). These observations indicate that B-BLMP7 and B-BLMP8
bind selectively to cancer cells outside the phage context.
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Figure 14: Validation of biotin-labeled HK-BLMP7 (B-BLMP7) and biotin-labeled HKBLMP8 (B-BLMP8) homing specificity to cancer cells in vitro (A-J). Streptavidin (Cy3)
immunofluorescence in murine parental and cisplatin-resistant 4T1.2 adenocarcinoma, murine
B16F10 melanoma, human MDA-MB-231 adenocarcinoma, and murine 3T3L1 fibroblast cell
lines. Cells were incubated with B-BLMP7 and B-BLMP8 for 6 hours. Red (Streptavidin)
immunofluorescence signal upon digital channel merging indicates localization of B-BLMP7
(Cy3) and B-BLMP8 (Cy3) on 4T1 parental, 4T1 cisplatin resistant, B16F10 and MDA-MB-231
cancer cell lines but not on 3T3L1 murine fibroblasts. Nuclear DAPI staining is blue. Scale bar:
50 m.
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10. Biotin-labeled HK-BLMP8 does not home to epithelial tumor cells in vitro
As discussed earlier, phage-displayed BLMP8 did not bind to epithelial cancer cells in
vitro (Figures. 13 E-H). In order to corroborate that the chemically synthesized B-BLMP8 also
demonstrated the same binding pattern, we investigated B-BLMP8 (red) homing in vitro with an
immunofluorescence assay, using a specific antibody against epithelial marker E-cadherin
(green). B-BLMP8 was incubated with murine parental and cisplatin-resistant 4T1.2
adenocarcinoma cells, murine B16F10 melanoma, and human MDA-MB-231 adenocarcinoma
cells for six hours.
As seen with phage-displayed BLMP8, B-BLMP8 (red) was observed to bind less to
cancer cells with pronounced E-cadherin (green) expression (green arrow). Instead, B-BLMP8
(white arrow) was seen to bind better to cancer cells with very little to no E-cadherin expression
(Figures. 15 A-D). Loss in the E-cadherin expression is a characteristic feature of cells undergoing
EMT, to acquire a more mesenchymal phenotype. Taken together, these data suggest that like
phage-displayed BLMP8, its synthetically synthesized version B-BLMP8 also binds to cells with
a more mesenchymal phenotype.
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Figure 15: B-BLMP8 homes to tumor cells expressing reduced levels of E-cadherin
(A-D). Streptavidin (Cy3) and anti E-cadherin (Alexas-488) immunofluorescence in murine
4T1.2 parental and cisplatin-resistant adenocarcinoma, murine B16F10 melanoma and human
MDA-MB-231 adenocarcinoma cancer cell lines. Cells were incubated with B-BLMP8 for six
hours. Upon digital channel merging, cancer cells exhibiting high level of green (E-cadherin)
immunofluorescence signal (green arrow), demonstrate lesser homing of B-BLMP8 (Cy3).
However, cancer cells exhibiting little to no green immunofluorescence signal (white arrow),
demonstrate more specific homing of B-BLMP8 (Cy3). Nuclear DAPI staining is blue. Scale bar:
50 m.
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11. HK-BLMP8 induces cell death in murine cancer cell lines in vitro
The ability of hunter-killer peptides to induce programmed-cell death in vivo and in
vitro is a well-documented phenomenon (145, 189-191). A cell viability assay using different
hunter-killer peptides was performed in murine parental and cisplatin-resistant 4T1.2
adenocarcinoma cells, B16F10 melanoma, and 3T3L1 fibroblasts cell lines. The cells were treated
with HK-BLMP7 (300 moles/L), varying concentrations of HK-BLMP8 (100-200 moles/L),
positive-control D-CAN (100 moles/L), and uncoupled (KLAKLAK)2 moiety (100 moles/L)
for 8 hours. Cell death was then evaluated through trypan blue staining.
At the eight-hour time point, D-CAN induced non-specific apoptosis in both murine
cancer cells and 3T3L1 fibroblasts (Figures. 16A and 16B). As previously described, no apoptosis
induction was seen upon treatment with the uncoupled (KLAKLAK)2 moiety owing to the
absence of a homing domain (Figures. 16A and 16B). Treatment with HK-BLMP7 induced no
cell death in any of the cells at the eight-hour time point. Upon treatment extension to twenty-four
hours, a small degree of cell death was observed in both murine cancer cell lines and 3T3L1 cells
(Figures. 16A and 16B). On the other hand, at the eight-hour time point, HK-BLMP8 induced
apoptosis at both 100 moles/L and 200 moles/L concentrations, specifically in murine cancer
cell lines (data not shown). To investigate if HK-BLMP8 induced apoptosis was cancer cellspecific, the treatment period was increased to twenty-four hours. At this new time point, HKBLMP8 induced complete cell death in nearly all cancer cell lines but not in 3T3L1 fibroblasts
(Figures. 16A and 16B). Although both HK-BLMP7 and HK-BLMP8 induce cancer cell
apoptosis in vitro, HK-BLMP8 was a more suitable candidate owing to its specificity to only
cancer cell lines and not 3T3L1 fibroblasts. Further, in vitro immunostaining corroborated that
HK-BLMP8 induced cancer cell line death via cleaved caspase-3 activation (Figures. 17 A-C).
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Figure 16: HK-BLMP7 and HK-BLMP8 induce apoptosis in cell culture
A. Cell viability assay of murine 4T1 parental, 4T1 cisplatin resistant, B16F10 and 3T3L1
fibroblast cell lines following treatment with uncoupled (KLAKLAK)2 (100 moles/L), DCAN (100 moles/L), HK-BLMP7 (300 moles/L) or HK-BLMP8 (100 to 200 moles/L).
Cell death was evaluated by Trypan blue staining. Uncoupled (KLAKLAK)2: negative control
and D-CAN: positive control.
B. Brightfield images of dead cells (Trypan blue positive) after treatment with uncoupled
(KLAKLAK)2 (100 moles/L), D-CAN (100 moles/L), HK-BLMP7 (300 moles/L) or HKBLMP8 (100 moles/L). Uncoupled (KLAKLAK)2: negative control and D-CAN: positive
control. Scale bar: 50 m.
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Figure 17: HK-BLMP8 induces cleaved caspase-3 mediated apoptosis in murine cancer cell
lines in vitro. Cleaved Caspase-3 (red) immunofluorescence in murine 4T1 parental, 4T1 cisplatin
resistant, and negative control 3T3L1 murine fibroblast cell lines treated with HK-BLMP8 (100
moles/L) for 8 hours. Red (cleaved caspase-3) signal upon digital channel merging indicates
cleaved caspase-3 labeling in cancer cell lines. Nuclear DAPI staining is blue. Scale bar: 50 m.
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12. HK-BLMP8 administration induces a modest reduction in 4T1 pulmonary metastatic
burden but does not improve overall survival
Based on the in vitro cell viability and cleaved caspase-3 staining results, we
investigated whether HK-BLMP8 peptide could be used for the therapeutic destruction of
pulmonary metastases. We injected spontaneously metastasizing dual-luciferase and mCherry
labeled 4T1 adenocarcinoma cells into Balb/c mice. Once the tumors became palpable, the mice
were randomized into two cohorts (n=5/cohort) and treated with vehicle control or 10 mg/kg HKBLMP8 subcutaneously for four weeks. Tumors were measured thrice a week. Further, the effect
of vehicle or HK-BLMP8 administration on metastatic progression was monitored weekly
through non-invasive bioluminescence imaging. Following the administration of the last dose, the
mice were monitored for survival analysis.
Based on Welch s t-test analysis, no significant difference (p=0.5735) in tumor
volumes was observed between the two groups during and after treatment (Figure. 18A). These
results suggest that the HK-BLMP8 administration did not affect primary tumor growth. Further,
the Log-Rank (Mantel-Cox) test demonstrated no significant difference (p = 0.9626) in OS
between the two groups (Figure. 18B). However, upon analysis of non-invasive bioluminescence
images of the mice, a significant difference in metastatic burden was indicated between the groups
(Figure. 18C). In the HK-BLMP8 treated mouse cohort, cancer progression and subsequent
pulmonary metastatic burden were significantly lower when compared to the vehicle-treated
mouse cohort (Figure. 18C). These observations were further corroborated through pulmonary
metastases nodule quantification. At the experimental endpoint, the mouse lungs were subjected
to PBS perfusion. The lungs were then fixed in formalin until the metastatic nodules were
bleached to amelanotic gray/white nodules (Figure. 18D). This was followed by a blind
enumeration of metastatic lung nodules of both mice cohorts. The HK-BLMP8 treated mice
demonstrated a significantly lower (p

0.01) pulmonary metastatic nodule burden when
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compared to the vehicle control group (Figure. 18E). Together, these data suggest that HKBLMP8 administration induces a modest reduction in metastatic burden, even though it does not
improve OS (Figure. 18).
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Figure 18: HK-BLMP8 administration reduces metastatic burden but does not
improve overall survival in vivo
A. Primary tumor growth curves for vehicle versus HK-BLMP8 treated cohorts (n = 5
mice/cohort). Vehicle and HK-BLMP8 (10mg/kg) were administered subcutaneously thrice
week, for twelve weeks. Tumor volumes were calculated using the formula : length x (width) 2
x 0.52. Tumor volumes are shown as mean ± SEM.
B. Survival of mice post vehicle or HK-BLMP8 (10mg/kg) administration was monitored. The
probability of survival was depicted using Kaplan-Meier curves. ns, p >0.05.
C. Non-invasive bioluminescence imaging to monitor the effect of vehicle and HK-BLMP8
(10mg/kg) on cancer progression and metastatic burden over five weeks. The luciferase signal
and luminescence were assessed in vehicle and HK-BLMP8 treated cohorts respectively.
D. Representative images of primary tumors and lung metastases in vehicle and HK-BLMP8
treated mice cohorts.
E. Quantification of metastatic nodules of vehicle and HK-BLMP8 treated mice cohorts (n = 5
/cohort) at experimental endpoint (**, p 0.01). Metastatic nodule number shown as mean ±
SEM.
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Chapter 5: Discussions
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Throughout disease progression, tumor cells undergo spatial and functional changes
that manifest in a complex sub-clonal architecture, further enhanced by the application of
chemotherapeutic drugs (192). The existence of spatial intra-tumoral heterogeneity accounts for
the initiation of tumor clonal evolution and subsequent chemoresistance. Tumor cell diversity
occurs due to progressive mutational changes that result in distinct cancer cell populations (193).
Relapse and metastatic progression after a positive therapeutic effect often occur due to a resistant
population that was present before therapy or originated as a result of chemotherapy. Survival,
proliferation, and subsequent dominance of this population could be due to features that were
absent before therapy. Thus, it is crucial to gain more insight into players implicated in the
survival of these chemotherapy-tolerant metastasis-inducing tumor cell populations.
TNBCs demonstrate a lack of response to targeted therapies. Therefore, chemotherapy
remains a mainstay in TNBC treatment. Although TNBCs demonstrate chemosensitivity, the
evolution of chemoresistance occurs over time. Drug resistance promotes TNBC relapse and is a
predilection for the development of distant metastases in organs such as the lung, brain, and liver
(194). TNBC s well-documented resistance to chemotherapy and aggressive phenotype provides
the ideal setting to study metastatic progression.

We selected the 4T1 murine mammary

adenocarcinoma model for our study as it accurately portrays stage IV human TNBC (195).
Moreover, it has been used to study chemotherapy-mediated metastatic progression (196, 197).
Upon primary tumor development in the 4T1 model, the DNA cross-linking agent
cisplatin was administered to inhibit cancer progression. The selection of this chemotherapeutic
agent was primarily due to the renewed interest in using platinum salts in the clinical management
of human TNBC (198, 199). Although the cisplatin administration failed to elicit any primary
tumor response, we report that it exacerbated pulmonary metastasis in the 4T1 murine model of
spontaneous metastasis. These observations suggest the possibility of a chemotherapy-induced
enrichment of tumor cell populations favoring metastatic progression. While the adverse side
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effects of chemotherapeutics have been observed for decades, the role played by chemotherapy
in actively triggering metastatic progression has only recently been brought to light (178, 200,
201).
Targeting these drug-tolerant metastases initiating tumor cells was our next logic step
forward. As described previously, phage display technology has been used in the isolation and
targeting of several molecular targets involved in carcinogenesis. While drugs targeting tumor
cells and other stromal components of the TME have been identified using this methodology, the
recognition of molecules for selective targeting of drug-tolerant TNBC metastatic tumor cells is
yet to be performed. We report the isolation of nine novel peptides by phage display (using a
combined 7-mer and 8-mer phage-displayed peptide libraries), which revealed high selectivity
and binding efficiency towards tumor cells in the pulmonary metastases of the 4T1 murine
adenocarcinoma model. Between each round of bio-panning, the BLMP clones were sequenced,
and nine different homing peptides were identified. In vivo enrichment and in vitro preference
towards the cisplatin-resistant 4T1.2 cells, demonstrated by BLMP7 (motif: CLRHSSKIC),
prompted its selection for further analysis. BLMP8 (motif: CRAGVGRGC) was also a candidate,
owing to its homing to both 4T1 and B16F10 melanoma cells that form lung metastases.
To further validate the binding affinity and to substantiate our proposed hypothesis,
phage-displayed BLMP7 and BLMP8 were intravenously injected into mice. The
immunofluorescence assay on formalin-fixed paraffin-embedded tissue sections of these mice
revealed a pulmonary metastases-specific tropism exhibited by both BLMP7 and BLMP8. The
homing of BLMP7 and BLMP8 was also observed in the liver. This can be explained by nonspecific entrapment of phage within the reticuloendothelial system of the liver (202, 203). Phage
homing specificity was further corroborated by the absence of BLMP7 and BLMP8 localization
in control organs such as the brain, kidney, and pancreas. Interestingly, in addition to the
pulmonary metastases, phage-displayed BLMP8 also exhibited tropism to primary 4T1 tumors.
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In the cisplatin-treated mice cohort, BLMP7 and BLMP8 localization patterns were
similar to that of the vehicle-treated cohort. Thus, this suggests that BLMP7 and BLMP8 homing
to metastases occur irrespective of chemotherapy in vivo. Interestingly, localization of BLMP7
and BLMP8 phage in the kidneys of cisplatin-treated mice was observed. We believe that
cisplatin-induced nephrotoxicity is partly responsible for the accumulation of phage in the
kidneys. To gain more insight into this unusual phenomenon, we analyzed the homing patterns of
BLMP7 and BLMP8 in healthy disease-free C57BL/6 mice. With the exception of liver
entrapment, neither BLMP7 nor BLMP8 demonstrated localization to kidneys or other control
organs.
To explore the possibility of BLMP homing to the metastases of other cancer types, the
localization of both BLMP7 and BLMP8 was further probed in the murine B16F10 melanoma
model of experimental metastasis. This model was selected due to lung colonization of the
implanted B16F10 melanoma cells (186, 187). Phage displaying BLMP8 demonstrated a high
binding efficiency to murine B16F10 cells in vitro. Like in the 4T1 murine model, BLMP8
demonstrated a chemotherapy-independent homing to the pulmonary metastases of the B16F10
murine model. However, BLMP7 showed no localization. Thus, this led us to conclude that
BLMP8 exhibits cross-tumor type reactivity and homes to pulmonary metastases regardless of
cancer subtype. In contrast, BLMP7 demonstrates binding only to TNBC cells. Despite BLMP7
and BLMP8 homing being independent of chemotherapy administration, their metastasis-specific
tropism bolsters the novelty of our findings. Further, it underscores the potential of using these
peptides in the development of metastases-specific therapeutics with potentially reduced offtarget effects.
Analysis of BLMP7 and BLMP8 distribution revealed localization along the invasive
edge of pulmonary metastases. This pattern was also demonstrated by BLMP8 in primary tumors.
In many cancers, including TNBC, metastasis is facilitated by the transitioning of tumor cells
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from a non-motile, epithelial phenotype into a migratory, mesenchymal-like phenotype via EMT
(28, 29). An EMT hallmark is the loss of epithelial cadherin (E-cadherin) expression and the
concomitant up-regulation of neural cadherin (N-cadherin) (204). This so-called cadherin
switch is associated with increased migratory behavior and inferior disease prognosis (33). A
major consequence of N-cadherin up-regulation is the loss of stable epithelial cell-cell adhesive
junctions, apicobasal cell polarity, and epithelial tissue structure, thereby facilitating the
dissemination of cancer cells from the primary tumor site. Thus, N-cadherin acquisition is a
critical step in metastatic progression (205).
An immunofluorescence assay was performed on formalin-fixed paraffin-embedded
tissue sections of mice injected with phage-displayed BLMP7 and BLMP8 inserts. When phage
co-localization with epithelial and mesenchymal cadherins was investigated, it was observed that
both phage-displayed peptides homed to tumor cells with up-regulated N-cadherin expression. No
phage was seen to bind E-cadherin-positive tumor cells in pulmonary metastases. An identical colocalization pattern was observed for phage-displayed BLMP8 in the primary tumors of the 4T1
spontaneous metastasis model, as well as for the pulmonary metastases in the B16F10
experimental metastasis model. These findings were further corroborated in cell culture, where it
was observed that phage-displayed BLMP7 and BLMP8 bound better to 4T1.2 murine
adenocarcinoma cells with reduced E-cadherin expression. Further, it was noticed both BLMP
clones bound to the cell line (TNBC) MDA-MB-231 model, described as a representative of the
mesenchymal phenotype of cancer cells (206). These results suggest that BLMP7 and BLMP8
have an affinity for tumor cells exhibiting mesenchymal-like characteristics. Although there are
several markers that have to be considered while defining the mesenchymal status of a cancer cell,
we segregated cells based on the level of E-cadherin expression (207). Reduced E-cadherin
expression is frequently correlated with increased invasion, making it an ideal marker for the
identification of metastatic tumor cells (208).
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Although localized primary tumors are the source of malignancy burden, it is the
metastases that attribute to over 90% of all cancer-associated morbidity and mortality (19). This
is the case even in TNBC (20, 209). Our in vivo phage-peptide library bio-panning has yielded
two metastasis specific peptides demonstrating a unique affinity towards tumor cells with
mesenchymal-like features. These findings prompted us to explore the therapeutic potential of
these peptides by translating them into agents targeting mesenchymal-like tumor cells, thus
curtailing tumor growth and progression. Previous studies have established a strategy of tumor
cell ablation via hunter-killer peptides (142, 169, 189). Based on this strategy, we successfully
coupled our pulmonary metastases homing peptides with an apoptosis-inducing (KLAKLAK)2
moiety (188).
Hunter-killer peptide versions of both BLMP7 and BLMP8 termed HK-BLMP7 and
HK-BLMP7 were synthesized as all D-amino acid peptides to minimize proteolytic cleavage. We
first validated biotin-labeled HK-BLMP7 and HK-BLMP8 internalization into mesenchymal-like
tumor cells. As expected, both HK-BLMP7 and HK-BLMP8 bound to tumor cells with reduced
E-cadherin expression outside the phage context. We next used these novel hunter-killer peptides
to reduce tumor cell viability in cell culture. Both HK-BLMP7 and HK-BLMP8 induced
concentration-dependent apoptosis. However, only HK-BLMP8 induced apoptosis specifically of
tumor cells. Investigation of HK-BLMP8 s mechanism of action revealed that it induced
programmed cell death via cleaved caspase-3 activation.
Given our results in cell culture, we proceeded to test HK-BLMP8 in vivo, using the
4T1 murine model of spontaneous metastasis. The goal of this study was to; a) determine the
working dose at which HK-BLMP8 might limit pulmonary metastatic nodule formation and, b)
explore if the reduction in pulmonary metastatic burden might affect overall survival. Using HKBLMP8, we observed a two-fold reduction in pulmonary metastastatic burden. However, the
statistical significance of this result is yet to be determined in repeated experiments with larger
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animal numbers. Peptide administration did not elicit any primary tumor response, nor did it
improve overall survival. The absence of primary tumor response corroborates HK-BLMP8 s
higher affinity for pulmonary metastases. It should be noted that we administered HK-BLMP8 at
a low dose (10mg/kg), to minimize off-target adverse effects on mouse health. The lack of survival
improvement could also be due to mice succumbing to metastatic burden at distant sites other
than the lungs.
The physiochemical properties of peptides due to electric charge may partly explain the
proclivity of the BLMP clones towards tumor cells. Both BLMP7 and BLMP8 have a net positive
charge. Therefore, their attraction and binding could be in part due to the negative charge of the
tumor cell surface (210, 211). However, peptide homing is also mediated by differentiallyexpressed receptors (179, 212, 213). Thus, we hypothesize that the BLMP clones might bear a
resemblance to the cancer-related ligands, owing to their specificity for tumor cells. To explore
this hypothesis, multiple sequence alignment and BLAST analysis were conducted. Through this
analysis, we were able to, a) identify promising cancer-specific ligands the BLMP clones were
homologous with, b) narrow down the cognate cancer putative receptors, and c) investigate if
these receptors mediated EMT activation since the BLMP clones homed to tumor cells with
mesenchymal features.
Multiple sequence alignment and BLAST analysis of BLMP7 and BLMP8 revealed their
resemblance to cancer-related proteins responsible for mediating chemoresistance and metastatic
progression. For BLMP7, BLAST analysis identified Mucin5B (MUC5B) to match BLMP7 with
a 66% amino acid similarity. The mucin family of proteins is often implicated in the progression
of human carcinomas and hematological malignancies (214). MUC5B is a secreted mucin
containing tandem repeat structures composed of prolines, threonines, and serines (214). Aberrant
MUC5B expression is mediated by injured alveolar epithelial cells in both idiopathic pulmonary
fibrosis (IPF) and lung adenocarcinomas (215, 216). Further, several IPF events such as fibroblast
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recruitment and proliferation, the formation of myofibroblastic foci due to EMT, ECM
accumulation, and lung remodeling are even observed in cancers (217). MUC5B regulates the IPF
phenotype by binding to the promoter region of NF- B and subsequently activating downstream
signaling (216). The significance of NF- B as a prognostic marker and its role in EMT and
metastasis has been well-elucidated in breast cancer (218, 219).
Blast Analysis of BLMP8, revealed a 100% amino acid identity with murine latent
transforming growth factor-beta binding protein 4 (LTBP4). LTBP4 serves as a TGF chaperone
and also maintains TGF R stability (220). Further, some studies also suggest that LTBP4 is a
crucial regulator of the TGF /TGF R signaling axis (221). Moreover, altered LTP4 expression
has been observed in the malignant tissue of both murine and human mammary carcinomas (222).
Overexpression of TGF triggers dysregulated TGF /TGF R downstream signaling, which is
often associated with chemoresistance, EMT induction, and metastatic progression (223, 224).
TGF signaling pathwa is a recogni ed mediator of breast cancer-associated chemoresistance,
EMT induction, and metastatic progression (223, 224).
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Chapter 6: Conclusions
and Future Directions
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In this study, we have successfully identified two novel peptides, BLMP7 and BLMP8
through in vivo phage-displayed peptide library screening against pulmonary metastases of the
4T1 murine model of spontaneous metastasis in the context of chemotherapy. To this end, no
other study has reported metastases-specific peptides. Our data show a high enrichment of the
selected peptides over several bio-panning rounds and selective binding to murine and human
tumor cell lines exhibiting mesenchymal-like features in vivo and in vitro. The evolution of novel
therapeutics targeting tumor cells with enhanced invasive and migratory potential is a promising
step in the clinical management and treatment of metastatic disease. Future analysis underlying
binding experiments for these peptides could be useful in the isolation of their cognate receptors.
Identification of these metastatic cell surface receptors will help gain more insight into their
downstream signaling mechanism counterparts and mechanisms.
Theranostic compounds are a promising class of radioactive contrasting agents. Over
the past decade, these agents have been instrumental in improving disease outcomes owing to
their ability to accurately facilitate whole-body and intraoperative imaging (225). The metastasesspecific tropism by the BLMP clones prompted us to explore the potential of developing these
peptides into malignancy-probing theranostic agents. In collaboration with Dr. Ali Azhdarinia
(MDACC, Houston), we are conjugating the BLMP clones to radiolabeled domains using
bifunctional DOTA and NODAGA chelators (226). We hope to delve deeper and gain more
insight into the mechanisms underlying cancer progression through near-infrared fluorescence
imaging with these compounds.
Targeted hunter-killer peptides represent a promising class of novel anti-cancer agents.
Their therapeutic benefit can be optimized by adjusting properties such as domain length, residue
placement, peptide hydrophobicity, and hydrophobic moment (227). Beyond this, future hunterkiller peptides might be designed to promote cell ablation using different cytotoxic domains. Our
results provide a glimpse at a potential anti-metastasis therapy combining two levels of
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specificit : homing to targeted cells and selective apoptosis of such cells upon internalization.
HK-BLMP8 is a novel pulmonary metastases-ablating peptide that demonstrates modest benefit
when employed in vivo. Through the conduction of detailed efficacy studies and the adjustment
of peptide properties mentioned above, we hope to potentiate this hunter-killer peptide candidate's
overall activity. We believe that using this hunter-killer peptide synergistically with classical
chemotherapy agents will not only push the boundaries of existing translational medicine but will
potentially revolutionize cancer therapy as it exists (228, 229).
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